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Abstract
The tumor suppressor protein p53 transactivates genes involved in cell cycle arrest and apoptosis in response
to DNA damage, cellular stress and some oncogenic proteins. The wild type polypeptide chain of p53 has four
distinct domains, including the sequence specific DNA binding core domain and the C terminal
tetramerization domain. p53 must retain its ability to oligomerize and bind DNA targets in vivo to fulfill its
function. Using X-ray crystallography and a crosslinking strategy, the structure of a wild type tetrameric p53
core domain bound to its consensus sequence was solved. This structure gives insight into DNA bend, core
domain-DNA binding cooperativity and surface residue conservation within the tetramer.
Many cancers result from cells harboring mutant forms of p53 that are unable to function due to their inability
to oligomerize, DNA binding defects or, in the case of human papillomavirus infection, p53 degradation.
High risk forms of the human papillomvirus (HPV) infect the basal layers of stratified epithelia and express
two oncoproteins, called E6 and E7, which can lead to cell cycle disruption and cervical cancer. E6 mediates
its cell transformation, in part, by forming a complex with the cellular E3 ligase E6-Association Protein
(E6AP) to target p53 for degradation by the ubiquitin- viii proteasome pathway. A high throughput solution
screen was designed to search for small molecule inhibitors of the E6 / E6AP interaction. Of the 80,000
compounds that were screened, 30 inhibitors with IC50 values in the low-micromolar to mid-nanomolar
range were confirmed using secondary assays. Two compounds were shown to specifically block p53
degradation and promote apootosis in cell lines infected with high risk forms of HPV. These HPV-E6
inhibitors provide a framework for developing HPV inhibitors with possible therapeutic applications.
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ABSTRACT 
  
THE TUMOR SUPPRESSOR PROTEIN p53 AND  
THE ANTAGONIZING ONCOPROTEIN E6 FROM HUMAN PAPILLOMAVIRUS TYPE 16 
 
Kimberly Ann Malecka 
Ronen Marmorstein 
 
The tumor suppressor protein p53 transactivates genes involved in cell cycle arrest and 
apoptosis in response to DNA damage, cellular stress and some oncogenic proteins.  The wild 
type polypeptide chain of p53 has four distinct domains, including the sequence specific DNA 
binding core domain and the C terminal tetramerization domain.  p53 must retain its ability to 
oligomerize and bind DNA targets in vivo to fulfill its function.  Using X-ray crystallography and a 
crosslinking strategy, the structure of a wild type tetrameric p53 core domain bound to its 
consensus sequence was solved.  This structure gives insight into DNA bend, core domain-DNA 
binding cooperativity and surface residue conservation within the tetramer.   
Many cancers result from cells harboring mutant forms of p53 that are unable to 
function due to their inability to  oligomerize, DNA binding defects or, in the case of human 
papillomavirus infection, p53 degradation.   
High risk forms of the human papillomvirus (HPV) infect the basal layers of stratified 
epithelia and express two oncoproteins, called E6 and E7, which can lead to cell cycle disruption 
and cervical cancer.  E6 mediates its cell transformation, in part, by forming a complex with the 
cellular E3 ligase E6-Association Protein (E6AP) to target p53 for degradation by the ubiquitin-
viii 
 
proteasome pathway.  A high throughput solution screen was designed to search for small 
molecule inhibitors of the E6 / E6AP interaction.  Of the 80,000 compounds that were screened, 
30 inhibitors with IC50 values in the low-micromolar to mid-nanomolar range were confirmed 
using secondary assays.  Two compounds were shown to specifically block p53 degradation and 
promote apootosis in cell lines infected with high risk forms of HPV.  These HPV-E6 inhibitors 
provide a framework for developing HPV inhibitors with possible therapeutic applications. 
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1.1 A Brief History of p53 
 
In 1979, several studies(DeLeo et al, 1979; Lane & Crawford, 1979; Linzer & Levine, 
1979; Rotter et al, 1980) were published that discussed the identification a new cellular protein.  
Unbeknownst to the researchers, their discoveries would spur the advancement of an entirely 
new research field that would come to encompass cell cycle regulation, apoptosis, cellular 
senescence and, perhaps most interestingly, cancer.  The 53 kilodalton (kDa) protein they 
discovered was coined p53(DeLeo et al, 1979). 
Today, the role of p53 as a tumor suppressor protein and its nickname of “guardian of 
the genome”(Lane, 1992) are well known, but in the time soon after its discovery, researchers 
were convinced that p53 was actually an oncoprotein.  Some early experiments even supported 
this hypothesis(Eliyahu et al, 1984; Jenkins et al, 1985; Jenkins et al, 1984a; Jenkins et al, 1984b), 
but its true function as a tumor suppressor and its importance in the cell has slowly been 
unraveled over the past thirty years. 
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1.1.1 The Cell Cycle 
One of the cell’s greatest successes is its ability to accurately reproduce itself.  Mitosis, 
the multi-step process of parent cell splitting into its two daughter cells, is only one part of a 
much bigger and highly regulated cycle that ensures fidelity upon cellular replication(Lodish et 
al, 2004).   
Broadly, the eukaryotic cell cycle is broken into four parts: G1, S, G2 and M (Figure 1.1).  
During the S phase, the entire DNA molecule, which is broken into individual chromosomes, 
carried within the cell is replicated.  During the M (mitosis) phase, the cell proceeds through the 
highly organized four phases (prophase, metaphase, anaphase, telophase) to accurately 
transport one entire set of chromosomes to each daughter cell.  The S and M phases are 
separated by growth phases (G1 and G2), during which mRNA is transcribed and translated to 
make proteins and prepare the cell for division(Alberts et al, 2002; Lodish et al, 2004). 
The eukaryotic cell cycle is regulated primarily by heterodimeric protein complexes 
comprised of both cyclins (regulatory subunit) and cyclin-depedent kinases (CDK, catalytic 
subunit).  Only when bound by a cyclin and thus directed to a substrate can a CDK 
phosphorylate its targets.  As cyclin concentrations change depending on where in the cycle the 
cell is, so do phosphorylation signals, which are used by the cell to exit one phase and enter 
another(Lodish et al, 2004).  This regulation is illustrated by the following basic example:  Near 
the end of the G1 phase, both G1 and S phase cyclin-CDK complexes are present in the cell, but 
the S phase complexes are bound by protein inhibitors.  When the cell is ready to enter the S 
phase, G1 cyclin-CDK complexes are directed to the inhibitors and disrupt their interaction to the 
S phase cyclin-CDK complexes by phosphorylation.  This signal leads to the inhibitors’ 
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polyubiquitination and subsequent degradation.  Now the S-phase cyclin-CDK complexes are 
free to phosphorylate the DNA replication machinery and begin the most important part of the S 
phase(Lodish et al, 2004). 
Since the cycle is so highly regulated, it should be no surprise that the cell has developed 
strategies to protect itself when things go awry.  The exact mechanism of this protection, in 
addition to how it related to cancer and oncogenic viruses, began to be more fully understood 
when p53 finally came on the scene. 
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Figure 1.1:  Schematic view of the eukaryotic cell cycle.   The phases of G1, S, G2, and M are 
shown as well as the major cyclin/CDK complexes that govern the progression of each phase.  
The figure is adapted from (Suryadinata et al, 2010). 
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1.1.2 Simian Virus (SV40) and p53’s discovery 
The simian vacuolating virus 40 (SV40) is intricately linked to the discovery of p53.  The 
virus, which belongs to the polyomavirus genus, has a double stranded DNA genome and is 
associated with tumors(Lowe et al, 2007).  In its host species of asian macaques, the virus does 
not cause any noticeable symptoms(Lowe et al, 2007).  However, when fetal hamsters were 
intracerebrally inoculated with the virus, four out of the seven resulting animals developed 
ependymomas(Kirchstein & Gerber, 1962).  Another study by Eddy et al. showed that sarcomas 
could be in induced in hamsters after inoculation with SV40(Eddy et al, 1961).   
Focus turned to one particular SV40 protein, known initially as protein A and currently 
as large T antigen.  It was known to be expressed early in viral infection and have a role in viral 
DNA replication.  Researchers wanted to study the individual protein but purification proved 
difficult because it was constantly pulling down other proteins that could have been either viral 
or cellular in origin(Tegtmeyer et al, 1975).   
Through a variety of experiments in 1979 and 1980(DeLeo et al, 1979; Lane & Crawford, 
1979; Linzer & Levine, 1979; Rotter et al, 1980), it was finally concluded that large T antigen was 
pulling down a cellular protein of 53 kDa, which Old and colleagues dubbed p53.  Exactly what 
p53’s role in the cell was had yet to be determined, however the fact that it was present in 
these tumor cells at higher levels than healthy cells lead researchers to believe it was an 
oncoprotein.  Lane et al. even speculated in their paper that “it may have a crucial role in the 
modulation of the transformed state.” 
Four years later, three experiments started to suggest that p53 was no oncoprotein.  
Maltzmann and Czyzyk showed that irradiating mouse cells with ultraviolet light, which caused 
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significant DNA damage, resulted in increased p53 levels(Maltzmann & Czyzyk, 1984).  Different 
forms of p53 could be found in cells depending on whether the cell was dividing or not(Milner, 
1984) and finally, Mowat et al. noticed differences in the TP53 (human p53 gene) gene of 
leukemia cells versus healthy cells(Mowat et al, 1985).   
This work was followed up by several studies that discovered p53 gene mutations in 
tumors and those affected with Li-Fraumeni Syndrome (FLS), which causes its sufferers to have a 
high susceptibility of childhood and adult cancers(Hollstein et al, 1991; Malkin et al, 1990; 
Srivastava et al, 1990).  Eliyahu et al. and Finlay et al. were also able to suppress tumor 
formation when cells were overexpressing wild type p53(Eliyahu et al, 1989; Finlay et al, 1989).   
Moshe Oren summed up all the current p53 research in 1992(Oren, 1992) by declaring p53 as 
the “ultimate tumor suppressor.” 
Today, the results of all these experiments are explained by the framework of p53’s 
known functions(Lowe et al, 2007) (Figure 1.2).  In response to DNA damage, cell stress and 
certain oncogenic proteins, p53 transactivates genes involved in bringing about one of three 
outcomes: 1. temporary cell cycle arrest, 2. permanent cell cycle arrest in the form of 
senenescence, 3. programmed cell death, also known as apoptosis(Lowe et al, 2007).  These 
processes are essential for removing defective cells from the actively dividing cell population.   
Consider a cell harboring detrimental mutations in its genome.  It is in the cell’s best 
interest to either fix these mutations (cell cycle arrest) or remove itself (senescence, apoptosis) 
so these mutations are not carried on to daughter cells; p53 ensures that these processes occur.  
If p53 is inactive and unable to fulfill this function, then this defective cell will continue through 
the cell cycle, divide and exponentially add defective cells to the population.  And, since nothing 
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is protecting these cells from gathering more deleterious mutations, they can easily go down the 
path of cellular transformation.  
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Figure 1.2: Overview of p53 signaling.  The diagram shows simplistically what proteins are 
activated in response to different stresses, how those proteins report to p53 and what the 
response of p53.  This figure is adapted from (Brown et al, 2009). 
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1.2 Functions of p53 in healthy cells 
 
1.2.1 Reasons for p53 activation 
When cultured, mouse embryonic fibroblasts (MEFs) will only actively divide for a short 
period of time compared with their human counterparts(Parrinello et al, 2003; Sherr & DePinho, 
2000).  Telomere shortening is a common reason for cell cycle arrest, particularly because it 
leads to chromosomal aberrations that may bring about cellular transformation.  However, 
MEFs have long telomeres and, in some cases, express telomerase.  So what else could be 
causing the cells to stop dividing?  Parrinello et al. assert that high oxygen concentrations (20%) 
stress the MEFs, cause DNA damage and result in the cultured cells arresting their cell cycles.  
This work went on to show that when the oxygen was dropped to the more physiological 
concentration of 3%, the cells did not enter senescence(Parrinello et al, 2003). 
Reasons for p53 activation and subsequent entrance into cell cycle arrest, senescence or 
apoptosis come in all forms (Figure 1.3).  One of the most common reasons is DNA damage.  
Gamma or UV irradiation, alkylation of the bases, depurination of the DNA, telomere 
shortening, substitution of the ribose sugar and even mismatching of DNA bases during 
replication are all reasons for the cell to stop itself(Levine et al, 2006).  Interestingly, all these 
problems have their own sets of guardians (proteins, pathways) that will detect and report to 
the cell the problems; the protein they all report to is p53.  The same is true for other types of 
cellular stresses such as hypoxia, H2O2 oxidative stress(Chen et al, 1998), glucose starvation, low 
ribosome biogenesis, damage to the cellular spindle and temperature shocks, among other 
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causes(Levine et al, 2006).  p53 will also respond if oncogenic proteins, such as RAS(Di Micco et 
al, 2007; Ferbeyre et al, 2002), E2F(Di Micco et al, 2007; Dimri et al, 2000),  
MOS(Di Micco et al, 2007), RUNX1(Wolyniec et al, 2009; Wotton et al, 2004) and RUNX1-
ETO(Wolyniec et al, 2009), become active.  Some other obscure stresses on the cell that invoke a 
p53 response are chemical inhibition of histone deacetylases (HDACs)(Munro et al, 2004) and 
depletion of chaperone proteins, such as Hsp70(Sherman et al, 2007).  All of these situations 
result in reports to p53 that something is not going well and the cell should seriously reconsider 
dividing. 
The fact that p53 is absent or nonfunctional in a large quantity of human cancers implies 
its importance and begs the question: why isn’t p53’s role in the cell backed up?  Why did 
Mother Nature not offer us an alternative pathway should the first one become totally mucked 
up?  The only answer that makes sense is that having one central protein receive all the 
information is far more efficient than several proteins receiving partial information.  The 
situation is simplified and leads to the most effective response(Levine et al, 2006).   
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Figure 1.3: Activation of p53 and its downstream events.  These two diagrams are a more 
detailed version of Figure 1.2 and show many of the proteins involved in p53 activation and 
which genes have their expression augmented by p53.  The question marks highlight areas 
where more work is needed to determine the effector proteins.  This figure is adapted from 
(Levine et al, 2006). 
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1.2.2 Cell Cycle Arrest and Senescence 
After receiving the news that there are problems in the cell, p53 responds by both 
increasing in concentration and binding to specific sequences of DNA to activate the 
transcription of genes that are involved in either cell cycle arrest/senescence or 
apoptosis(Levine et al, 2006; Zuckerman et al, 2009).  If the problem is minor and can be fixed, 
such as a few mismatched base pairs that were missed during editing in the S phase, then the 
cycle is stopped long enough for repair and it re-enters the cell cycle(Campisi & d'Adda di 
Fagagna, 2007).  If the problem is more serious, like an irreparable DNA lesion, then arrest is 
maintained in the form of senescence or the cell undergoes apoptosis(Zuckerman et al, 2009). 
p53’s response to induce cell cycle arrest is well illustrated through the following 
example.  In normal cells, pRb is bound to a protein known as E2F.  Near the end of the G1 
phase, CyclinE/Cdk2 targets pRb for phosphorylation, which disrupts its interaction with E2F and 
is one of the main signals for the cell to enter the S phase(Zamanian & La Thangue, 1993).  In 
cultured MEFs that have been stressed, it was shown that p53 stimulates the transcription of 
p21WAF1, which is an inhibitor of CyclinE/Cdk2 function.  Hence, transcription of p21WAF1 keeps 
the cell in the G1 phase until the stress is removed(Smogorzewska & de Lange, 2002).  
p53 induces the expression of other inhibitors of cell cycle cyclin/Cdk complexes, such as 
Gadd45 and 14-3-3.  Gadd45 inhibits Cdc2-cyclinB complex formation(Jin et al, 2000; Zhan et al, 
1999) while 14-3-3 binds to and sequesters Cdc2-cyclin B and cdc4525c to the cytoplasm(Chan 
et al, 1999; Peng et al, 1997).   p53 can also work by repressing gene expression to stall the cell 
cycle.  In particular, it represses Cdk4(Spurgers et al, 2006), cyclinE2(Spurgers et al, 2006), 
cdc25a, and cdc25c(Rother et al, 2007; St Clair et al, 2004).   
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In contrast to cell cycle arrest, senescence is when the cell leaves the cell cycle for an 
extended period of time or even permanently.  Several pathways that bring about senescence 
by way of p53 are well understood and three pathways, ARF, PAI-1 and PML, have been 
characterized. 
In a healthy cell, p53 levels are typically low and are turned over as fast as every 6 – 20 
minutes(Levine et al, 2006).  The main regulator of p53 levels is an E3 ligase protein known as 
Mdm2, which works in a negative feedback loop with p53 (Figure 1.4)(Lee & Gu, 2010).  p53 
stimulates the transcription of Mdm2, but Mdm2 binds to the N terminal transactivation domain 
of p53 to fulfill two functions: 1. blocking p53’s ability to interact with transcriptional machinery 
to successfully transactivates downstream genes and, 2. marking p53 for degradation by the 
ubiquitin-proteasome pathway(Lee & Gu, 2010).  In this way, as p53 levels go up so do Mdm2 
levels, which then lead to greater p53 degradation and less Mdm2 transcription.  The two 
proteins keep each other in check.  This regulatory protein’s role is so important in the cell that 
a knockout of the Mdm2’s gene is embryonic lethal in mice(Luna et al, 1995). 
When the tumor suppressor protein ARF (p14ARF in humans, p19ARF in mouse) is 
upregulated, p53 is activated.  This occurs because ARF binds MDM2 (HDM2 in humans) and 
inhibits its binding to p53, which in return increases p53 levels(Gil & Peters, 2006; Haupt, 2003).  
Higher protein levels of ARF are commonly seen in murine cells that have entered senescence 
and it appears to be required for both telomere and non-telomere-induced senescence in 
MEFs(Sharpless et al, 2004).   
The expression of plasminogen activator-inhibitor-1 (PAI-1) is regulated by p53 binding 
to its mRNA at the 3’-UTR, which leads to increased PAI-1 levels(Shetty et al, 2008).  PAI-1 is 
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used as a common marker of senescent cells(Mu & Higgins, 1995; Serrano et al, 1997) and, 
interestingly, once PAI-1 is downregulated, cells exit senescence(Kortlever et al, 2006). 
Finally, the promyelocytic leukemia (PML) tumor suppressor protein responds to the 
upregulation of the oncogene RAS by binding to CBP/p300 and marking p53 for acetylation at 
Lys382.  p53 is now stabilized as a result of the acetylation and induces other genes that lead 
the cell towards senescence(Ferbeyre et al, 2000; Pearson et al, 2000).  Pearson et al. were also 
able to show that PML -/- fibroblasts lose their ability to enter senescence upon Ras 
activation(Pearson et al, 2000) 
What specifically causes p53 to choose cell cycle arrest or senescence versus apoptosis 
is still widely unknown(Levine et al, 2006; Zuckerman et al, 2009).  The response in each cell is 
greatly affected by the intensity and duration of the stress signal(Espinosa, 2008).  Researchers 
have also realized that the status of p53 at the time of the signal also affects the outcome, 
where they define p53’s status as conformation, localization, activity, and stability status 
(CLASS)(Espinosa, 2008).  This remains an active area of research at this time(Campisi & d'Adda 
di Fagagna, 2007; Zuckerman et al, 2009). 
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Figure 1.4: MDM2 and p53 interaction.  The negative feedback loop involving p53 and its 
regulator protein MDM2 is depicted.  This figure was adapted from (Hardcastle, 2007). 
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1.2.3 Apoptosis 
The term apoptosis comes from the Greek words apo (from) and ptosis (falling) and was 
first described by Carl Vogt in 1842(Kerr, 1965).  As opposed to necrosis, which is a chaotic and 
often messy cell death, apoptosis is the very organized destruction of a cell and is governed by a 
strict set of signals(Alberts et al, 2002).   
Apoptosis can be induced either extrinsically (signals begin outside the cell) or 
intrinsically (signals are sent by the cell itself) (Figure 1.5).  Regardless of how the cell decides to 
apoptose, both pathways lead to the activation of proteases that are held in an inactive 
conformation, known as procaspases, until an apoptotic signal reaches it and uninhibits it, thus 
making an active caspase(Alberts et al, 2002).  Initiator caspases (8 and 9) are the first to be 
uninhibited, which then target many effector caspases (3, 6 and 7) for activation and lead to all 
sorts of signals such as permeabalization of the mitochondria, destruction of the cellular 
cytoskeleton, and cleavage of the genomic DNA.  During this time, the dying cell also displays 
markers on its surface that tell the surrounding cells about its death.  Eventually, the 
surrounding cells can internalize pieces of the dying cell (phagocytosis), such as DNA nucleotides 
and amino acids, to use in their own functions(Alberts et al, 2002).   
Extrinsic apoptosis begins by the binding of a ligand to a cell surface death receptor, 
such as Fas or tumor necrosis factor-α (TNF-α) receptor 1, by Fas ligand or TNF-α related 
apoptosis-inducing ligand (TRAIL)(MacFarlane & Williams, 2004).  Upon binding, effector 
proteins, such as the Fas-associated death domain (FADD), are recruited to the receptor to 
activate caspase 8 and begin the caspase cascade(Alberts et al, 2002; MacFarlane & Williams, 
2004). 
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Interestingly, p53 has been implicated in inducing the expression of Fas, TRAIL receptor 
2(Haupt et al, 2003), TRAIL death ligand (TNFSF10) and the Fas death ligand (FasL)(Kuribayashi 
et al, 2008; Maecker et al, 2000), which suggests that p53 can influence apoptotic signaling.  
Other genes involved in the apoptotic pathway, such as apaf-1, caspase 8 and caspase 6 also 
seem to be influenced by p53 activation(Haupt et al, 2003).   
Intrinsic signals for apoptosis are initiated by cell stress and act first upon the 
mitochondria.  Bcl2 family members, which are comprised of both pro- and anti-apoptotic 
proteins, coordinate to create pores in the mitochondrial membranes and release cytochrome c, 
which then coordinates with apoptotic protease-activating factor 1 (Apaf-1) to activate caspase 
9 and the subsequent caspase cascade(MacFarlane & Williams, 2004). 
To help out this intrinsic pathway, p53 induces the expression of OKL38, which in turn 
localizes to the mitochondria and helps release cytochrome c.  Yao et al. showed that inhibition 
of OKL38 expression resulted in an increase of tumorigenesis while an overexpression induced 
apoptosis in tumor cell lines(Yao et al, 2008).  Also working at the mitochondrial outer 
membrane, where it inserts itself and brings about pore formation, is the protein Bax(Vaseva & 
Moll, 2009).  p53 induces the expression of Bax, as well as the pro-apoptotic genes bid, puma 
and nox, while repressing expression of anti-apoptotic proteins(Vaseva & Moll, 2009).   
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Figure 1.5: The intrinsic and extrinsic apoptosis pathways.  The two signal pathways that 
propagate apoptosis is shown; both intrinsic (left) and extrinsic (right) signals are depicted in 
greater detail than described in the text.    This figure was adapted from (MacFarlane & 
Williams, 2004). 
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Intriguingly, p53 has also been shown to bring about apoptosis in a transcription-
independent fashion, most notably by localization to the mitochondria.  Marchenko et al. 
showed that following a p53-dependent apoptotic signal, a fraction of the p53 population 
rapidly headed for the mitochondria and resulted in cyctochrome c release(Marchenko et al, 
2000).  In a follow up work by the same laboratory, Moll and colleagues evidenced that p53 
formed complexes with both Bcl-XL and Bcl2, facilitating cytochrome c release in irradiated 
thymocytes(Mihara et al, 2003).   
Clearly, p53’s role in cell cycle arrest, senescence, and apoptosis is varied and necessary.  
Through both transcriptional-dependent and independent pathways, the protein mediates its 
function to augment the cell cycle and protect the cellular population from unwanted problems. 
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1.3 Cellular transformation and cancer 
 
According the American Cancer Society, cancer is defined by “the uncontrolled growth 
and spread of abnormal cells.”(Society, 2010)  All cancers arise due to mutations or malfunctions 
of the genes involved in cell cycle control(Society, 2010).  Only 5% of cancers are hereditary so 
the remaining cases are due to the cellular damage that occurs during a person’s lifetime.  In 
fact, 78% of cancer cases are diagnosed in those 55 years and older(Society, 2010).  Due to 
recent advances, the 5 year survival rate for all patients diagnosed between 1999 and 2005 is up 
to 68%(Society, 2010).  Research in novel cancer therapies is targeting new pathways, proteins, 
and cells from different angles all the time.   
In a review by Lane and colleagues, it is claimed that nearly 11 million people have 
tumors harboring TP53 genes which code for inactive protein while another 11 million have 
tumors in which other proteins involved in the p53 pathway are nonfunctional(Brown et al, 
2009).  Loss of p53 function appears to be one of the main risk factors for developing cancer 
over a person’s lifetime and p53 can be inactivated by mutation, gene loss or, as we will see, 
viral infection. 
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1.3.1 General loss of p53 function 
Typically, loss of p53 function happens in one of two ways: 1. Point mutations in the p53 
gene or 2. Abrogation of protein(s) function that is/are involved in the p53 signaling 
pathways(Brown et al, 2009).   
The full length, wild type, human p53 protein is 393 amino acids and is comprised of 
four domains: the N terminal transactivation domain, the sequence specific DNA binding domain 
(p53DBD), the tetramerization domain and the C terminal regulatory domain.  Interestingly, 50% 
of all the tumors bear mutations in the p53 gene(Wang & Sun, 2010) and 95% of these 
mutations are found in the DNA binding domain of the protein (Figure 1.6), which underscores 
the importance of p53’s transactivating function to the cell.  What is even more shocking is that 
some mutants of p53 are thought to actually gain functions that promote tumorigenesis 
(review(Brosch & Rotter, 2009)).  Many researchers are focused on developing drugs that can 
“re-activate” p53’s wild type properties and turn a mutant p53 into a fully functional tumor 
suppressor.  Several candidates are currently going though preclinical and Phase 1 drug trials 
(Table 1.1).   
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Figure 1.6: Cancer derived p53 mutations.  The full length protein of p53 is shown schematically 
and three domains are defined.  The relative number of times and placement of a particular 
point mutation is depicted as a histogram above the schematic.  The majority of tumor-derived 
mutations are found in the core/DNA binding domain.  This figure was adapted from (Cho et al, 
1994). 
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Table 1.1: Small molecule modulators of p53 and their drug trial status.  Several known small 
molecules capable of stabilizing p53 levels through various mechanisms and their current stage 
in drug trials are listed.  This table was adapted from (Brown et al, 2009). 
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In some cancers, the p53 gene is lost all together.  Gene therapy is actively being 
attempted to reintroduce a wild type p53 gene to these lacking cells.  For example, Ad-p53 is a 
replicative-defective adenovirus that bears wild type p53 to the cell with reasonable efficiency 
and low toxicity.  Marketed under the name Gendicine or Advexin, the technique is currently in 
phase 1 clinical trials in the United States and seems to be particularly useful against head, neck, 
and lung cancers at inducing growth arrest and apoptosis.(Brooks & Gu, 2003; Pearson et al, 
2004; Roth, 2006) 
Obviously cancers can also exist when p53 is still present in its wild type form but unable 
to function due to members of its pathway being functionally defective(Wang & Sun, 2010).  The 
best example of this is when Mdm-2 turns oncogenic by way of over-actively degrading p53, 
which occurs in nearly 7% of all human cancers(de Rozieres et al, 2000; Luna et al, 1995; 
Momand et al, 1998).  Small molecules, including nutlins, benzodiazepinediones (BDA) and some 
spiro-oxindoles derivatives have been developed to inhibit Mdm2 degradation and bring about 
p53 function (Review (Wang & Sun, 2010)).  This type of therapy comes with some controversy 
because these compounds could incorrectly activate p53 in healthy cells or over-activate 
Mdm2’s interaction with other known partner proteins that could lead to adverse 
effects(Ambrosini et al, 2007; LaRusch et al, 2007; Lau et al, 2008). 
 
 
 
 
26 
 
1.3.2 Loss of p53 in tumor viruses 
Cancerous tumors can also arise due to viral infection because the virus has found a way 
to circumvent p53 function.  The fact that one of large T antigen’s jobs in SV40 infection was to 
bind p53, which explained why the two proteins were consistently purified together, and 
sequester it from service is neither surprising nor unique.   
Once inside a cell, the goal of a viral particle is to replicate itself.  For this to occur, the 
cell needs to be forced into DNA replication, which is a tightly regulated cellular process.  It 
should come as no surprise that when a virus forces the cell into the S phase, it also has a back- 
up plan to deal with the inevitable cellular p53 response. Since cell cycle arrest, senescence or 
apoptosis are not conducive to viral replication, many viruses have evolved ways to circumvent 
this problem.  For SV40, it was large T antigen’s binding to p53.  For others, like the 
adenovirus(Berk, 2005) and human papillomavirus(Huibregste et al, 1993; Scheffner, 1998; 
Scheffner et al, 1993), it is degradation of p53.  From here, the cell cycle is completely 
dismantled, p53 is out of commission and cellular transformation is a very common result.   
As already described, SV40 is a polyomavirus that has been shown to cause 
tumorigenesis in hamsters(Eddy et al, 1961; Kirchstein & Gerber, 1962).  After the polio vaccine 
was accidently contaminated with SV40 and administered to patients between 1955 and 1963, a 
huge uprising of concern followed.  Interestingly, no firm data exists that SV40 can cause cancer 
in humans with any frequency or severity as it is seen in animals(Poulin & DeCaprio, 2006).  
However, Merkel cell polyomavirus (MCV) has recently been described and is associated with 
human skin cancers(Feng et al, 2008).  In addition, both the adenovirus family(Huebner et al, 
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1962; Rabson et al, 1964) and the human papillomavirus family(Huibregste et al, 1993; Scheffner 
et al, 1993) have been linked to animal and human cancers.   
These small, DNA tumor viruses have three interesting things in common: they all have a 
protein to push the cell in the S phase, they all have a protein that will take care of p53’s 
response and they all integrate their DNA into the host’s chromosome (Review(Levine, 2009)).  
Large T antigen, E1A and E7 (from SV40, human adenovirus, and human papillomavirus, 
respectively) were all shown to bind and inactivate pRb, with the result being premature 
entrance into the S phase.  Obviously p53 takes offense to this and responds accordingly.  In 
return, large T antigen, E1b-55K and E6 (from SV40, human adenovirus and human 
papillomavirus, respectively) were all shown to bind and inactive p53(Levine, 2009) (Table 1.2). 
Cancer is an unfortunate by-product of these viral infections and not the main goal.  
Bear in mind that host death is not beneficial to viruses either so, especially in the case of 
human papillomaviruses, transformation is a slow process, oftentimes taking many 
years(Scheffner, 1998).  Similarly, when p53 is mutated or simply missing from the cell, cancer is 
the inevitable outcome.  These situations only serve to highlight the importance of cell cycle 
arrest, senescence and apoptosis to every person’s life. 
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Table 1.2: Three DNA tumor viruses and their similar proteins.  The three DNA tumor viruses 
that are known to cause cancer in both humans and animals are listed.  All three viruses have 
evolved proteins that will interact with pRB to push the cell in to the S phase and a protein to 
inactive p53.  The proteins, along with their names and functions are listed.  This figure was 
adapted from (Levine, 2009). 
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1.4 Overview of dissertation 
 
This dissertation will focus on p53 activity in terms of wild type function and loss of 
function due to human papillomavirus infection.  Chapter 2 will explore how the wild type p53 
DNA binding domain binds to its consensus sequence as a tetramer, which is essential for p53 
transactivation of downstream genes in cell cycle arrest, senescence and apoptosis.  Previous 
work with the domain has identified why certain mutations render p53 inactive and offer 
insights into p53 function.  The tetramer structure is the next step and represents the first time 
all four DNA binding domains have been seen bound to a full consensus sequence together and 
depicts one way the protein binds to DNA in vivo.  Chapter 3 will focus primarily on human 
papillomavirus type 16 E6, its interaction with the E6 Associating Protein (E6AP) and how these 
two proteins bring about degradation of p53 during infection.  Specifically, the project sought to 
identify small molecules capable of disrupting the E6 / E6AP interaction, which would inhibit p53 
degradation and bring about senescence or apoptosis in cell lines harboring an integrated 
human papillomavirus genome. 
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CHAPTER 2 
Crystal Structure of a p53 core tetramer bound to DNA 
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2.1.   Introduction 
 
 
2.1.1. p53 polypeptide and its consensus sequence for DNA binding 
 
The full length human p53 protein is 393 amino acids and comprised of four domains: the N 
terminal transactivation domain, the sequence specific DNA binding (DBD) or core domain, the 
tetramerization domain, and the C terminal regulatory domain (Figure 2.1).  Although dimers 
have been shown to mediate transactivation of downstream genes in cells (Pietenpol et al, 
1994), the functional quaternary structure of p53 in vivo is a tetramer. 
The N terminal transactivation domain, which interacts with the cellular transcripitional 
machinery to promote gene transcription, has tricky designation(Viadiu, 2008).  The full domain 
is residues 1 – 92 and can be broken into two subdomains based on amino acid sequence.  
Residues 1 – 64, which have several aspartic and glutamic acids, are considered the 
transactivation domain while residues 65 – 92 are the obviously named proline-rich domain.  
However, the full domain can also be broken into two different subdomains.  Residues 1 – 42 
are called transacriptional activation domain 1 (AD1) and residues 43 – 92 are transcriptional 
activation domain 2 (AD2).  Interestingly, AD1 appears to promote transcription of cell cycle 
arrest genes while AD2 promotes transcription of genes involved in apoptosis(Harms & Chen, 
2006). 
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Figure 2.1: The p53 polypeptide.  The full length human p53 protein is shown schematically with 
each domain represented as colored blocks. 
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The tetramerization domain runs from amino acids 324 – 361(Jeffrey et al, 1995; Viadiu, 
2008) and has a simple structure(Jeffrey et al, 1995).  Each domain consists of a ß strand 
(residues 326 – 333) and an α helix (residues 335 – 354).  The crystal structure solved by  Jeffrey 
et al. shows that four tetramerization domains come together as a dimer of dimers.  A dimer is 
formed by two ß strands, which come together to form an anti-parallel ß sheet, while the two α 
helices form an anti-parallel α helical interface.  Two of these dimers come together via the 
alpha helices to create the tetramer(Jeffrey et al, 1995) (Figure 2.2).   
The regulatory domain is composed of many lysines and arginines to create a very basic 
region of the protein.  This is the area where most of the post-translational modifications will 
occur, such as methylation, phosphorylation, acetylation, and ubiquitination(Viadiu, 2008).   
Arguably the most interesting domain of p53 is the DNA binding (DBD), or core domain.  This 
sequence specific binding region of the protein is composed of amino acids 93 – 292 and 
harbors the vast majority of tumor-derived p53 mutations(Cho et al, 1994; Viadiu, 2008).  This 
region has been shown to bind the WAF1 element with a Kd of 83 ± 1.4 nM.  The domain also 
binds the DNA cooperatively, with only tetrameric species present after DNA/domain 
incubation(Balagurumoorthy et al, 1995). 
In 1992, Vogelstein and colleagues set out to determine the sequence of DNA to which the 
DBD typically binds.  Using fragmented human genomic DNA, they identified a consensus 
sequence with “striking internal symmetry”(El-Diery et al, 1992).  The full sequence consists of 
two sets of ten base pairs that follow the motif of 5’-Pu Pu Pu C (A/T) | (T/A) G Py Py Py -3’.  The 
ten base pairs can be placed directly next to each other (icosamers) or separated by up to 13 
base pairs(El-Diery et al, 1992).   
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A follow up work by McLure et al. determined that isolated DBDs would first bind to 
consecutive, but not alternating, quarter sites (Figure 2.3).  This work, as well as Weinberg et al., 
greatly supported the conclusion that tetrameric p53 binds DNA cooperatively 
(Balagurumoorthy et al, 1995) by showing that tetramers have at least 50 fold greater binding 
affinity than dimers alone(McLure & Lee, 1998) and that a tetramer/DNA complex had an 
approximate t1/2 of 15 minutes while dimer/DNA complexes had an approximate t1/2 of 30 
seconds(Weinberg et al, 2004). 
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Figure 2.2: Tetramerization domain of p53, 1C26.  Individual tetramerization domains of p53 
are shown in yellow, green, blue and purple.  The yellow/green and blue/purple pairs represent 
dimers where the ß strands have come together to form an anti-parallel ß sheet while the α 
helices form an anti-parallel α helical interface.  The α helices then come together to form the 
full tetramer, which is a dimer of dimers.  This figure is adapted from (Jeffrey et al, 1995). 
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Figure 2.3: Pentamers of full p53 consensus sites.  Arrows represent pentamers following the 
consensus sequence requirements while dashes a represent random DNA sequence.  All were 
tested for DNA binding.  CON (positive control), M34 and H1 were all found to bind full length 
p53 in vitro, while M34 and NB (negative control), and m2 showed no appreciable binding.  This 
figure is adapted from (McLure & Lee, 1998). 
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2.1.2. Previously solved p53DBD structures: 1TSR, 2OCJ, 1HU8 
 
The core domain of p53 has been extensively studied by X-ray crystallography.  The first 
structure, which was published in 1994 by the Pavletich laboratory, consisted of one human p53 
core domain bound sequence-specifically to its quarter site(Cho et al, 1994).  Following this 
landmark paper, the structure of both the human(Wang et al, 2007) and mouse(Zhao et al, 
2001) p53DBDs in the absence of DNA were also solved. 
The first p53DBD structure, which has the protein databank (PDB) code of 1TSR, provided 
the structural information of the domain bound to DNA, in addition to explaining why several 
tumor-derived p53 mutations were deleterious to protein function.  The central part of the 
domain consists of a 4 stranded and 5 stranded anti-parrallel ß sheet that packs together as a 
sandwich.  The strands are highly twisted leading to two very different ends of the sandwich; 
one end is compact with short loops while the other splays to the loop-sheet-helix motif, which 
is responsible for DNA binding and contains the tetrahedrally bound Zn2+ ion (Figure 2.4)(Cho et 
al, 1994). 
Careful analysis of this structure highlights cancerous mutations that fell into two 
categories: 1. domain stabilization (ex. Arg175, Gy252, Arg249, Arg282) and Zn2+ ligation 
(Cys176, His179, Cys238, and Cys242) , 2. DNA binding (ex. Arg248, Arg273).  Domain 
stabilization mutants comprise 21.7% of tumor-derived p53 mutations, while DNA binding 
mutants are 18.4%.  This work underscores the importance of p53’s ability to fold properly and 
bind DNA to successfully carry out its function(Cho et al, 1994). 
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Figure 2.4: Structure of human p53DBD bound to DNA, 1TSR.  The core domain of human p53 
bound to DNA is represented above.  The colored areas highlight the loop-sheet-helix motif and 
highly conserved regions of the domain.  Red: S8, L3 loop, S9; Blue: H1 helix; Yellow: S3, L1 loop, 
S2’, and S2; Pink: S10 and H2 helix.  This figure is adapted from (Cho et al, 1994). 
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Seven years later, the structure of the mouse p53DBD in the absence of DNA was solved 
(1HU8) and, in 2007, the human p53DBD without DNA structure (2OCJ) was solved(Wang et al, 
2007; Zhao et al, 2001).  The sequence identity between mouse and human p53 core domains is 
85% meaning that structurally these domains should be nearly identical(Gasteiger et al, 2003).  
Both structures show that when not bound to DNA, the domain has largely the same 
conformation (Cα  root mean square deviation (RMSD) of ≤ 0.87 Å) leading to the conclusion that 
DNA binding does not lead to a gross structural rearrangement of the domain(Wang et al, 2007; 
Zhao et al, 2001) (Figure 2.5) (Figure 2.6).  One area of the mouse structure that does show a 
difference is the L1 loop, which contains several amino acids involved in DNA binding and would 
need to undergo a structural change when DNA was present(Zhao et al, 2001). 
Zhao et al. also report that the domain crystallized as a noncrystallographic trimer, where 
each subunit-subunit interaction is nearly identical (Figure 2.7).  The dimers created in this unit 
cell were incompatible with DNA binding and the authors postulate that this represents a 
physiological, but inactive form of p53(Zhao et al, 2001).  It is interesting to note that similar 
contacts are seen between two p53DBDs in the unit cell of 1TSR, where three DBDs are present 
but only one is bound sequence specifically(Cho et al, 1994). 
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Figure 2.5: Structure of human p53DBD, 2OCJ.  The human p53DBD in the absence of DNA is 
shown.  The Cα RMSD with 1TSR is ≤ 0.87 Å, indicating that the domain does not undergo any 
significant structural rearrangement upon binding DNA.  This figure it adapted from (Wang et al, 
2007). 
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Figure 2.6: Structure of the mouse p53DBD, 1HU8.  The mouse p53DBD in the absence of DNA 
is shown.  The Cα RMSD with 1TSR is ≤ 0.87 Å, indicating that the domain is structurally the same 
as human p53DBD and does not undergo any significant structural rearrangement upon DNA 
binding.  This figure it adapted from (Zhao et al, 2001). 
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Figure 2.7: Noncrystallographic trimer of 1HU8.  The asymmetric unit for 1HU8 crystal packing 
is shown.  Each subunit is individually colored as red, blue or green with the key structural 
aspects labeled.  This figure is adapted from (Zhao et al, 2001). 
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2.1.3. Convertible Nucleoside Approach and Crosslinking 
 
Twelve years followed the landmark paper of Cho et al. before the first higher order 
structure of p53 bound to DNA was published(Ho et al, 2006).  Efforts to crystallizing these 
structures face difficulties, which are highlighted well by looking at the unit cell of 1TSR(Cho et 
al, 1994).  The DNA used in that study is a half site, meaning that two p53DBDs could bind 
sequence specifically.  While three p53DBDs are present in the unit cell, only one is bound 
sequence-specifically (Figure 2.8)(Cho et al, 1994).  It is possible that harsh crystallization 
conditions, strong interactions between the domains and competing core domain dimers that 
are unable to bind DNA(Zhao et al, 2001) could hinder crystallization.  A method was needed to 
ensure that the domains would remain bound to the DNA properly from purification through 
data collection. 
The solution employed by Ho et al. was the convertible nucleoside strategy and subsequent 
crosslinking of the p53DBD protein to the DNA(Ho et al, 2006).  A quick look at the 1TSR 
structure shows that Cys277 points in the major groove and makes a base-specific contact with 
a cytosine in the purine region of the consensus sequence(Cho et al, 1994).  If the cytosine is 
replaced with a similar nucleoside bearing a sulfhydryl, Cys277 is perfectly placed for creating a 
disulfide bond (crosslink) between the protein and the DNA(Verdine & Norman, 2003).  
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Figure 2.8: Asymmetric unit of 1TSR.   The asymmetric unit of 1TSR is shown.  Three p53DBDs 
are present and colored individually (red, yellow and purple).  The DNA half site used for 
crystallization is colored in blue.  The yellow domain is bound sequence specifically to its quarter 
site while the red domain is weakly bound at a nonconsensus site.  The purple domain makes no 
contact with the DNA at all, but does make protein-protein interactions and stabilizes crystal 
packing.  This figure is adapted from (Cho et al, 1994). 
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Introducing a crosslink between protein and DNA is especially useful under certain 
situations.  Typically for complex crystallization, the Kd should be greater than 10 nM, however 
many physiological interactions are considerably weaker.  This problem has left gaps in the 
structural record, but recent advances with crosslinking have started to fill in the holes(Verdine 
& Norman, 2003). 
Photo-crosslinking is the most widely used technique to covalently link DNA to a 
protein(Verdine & Norman, 2003).  Nucleosides like 5-bromouracil, 5-iodouracil(Willis et al, 
1993), or 8-azido-dA(Liu et al, 1994) can be incorporated into DNA then activated to form 
crosslinks with protein by subjecting them to the proper wavelength of light.  Unfortunately, 
yields are typically low (10 – 20%) and high energy intermediates can lead to biologically 
irrelevant structures that make this technique essentially useless for structural studies(Verdine 
& Norman, 2003). 
A far better technique for crystallography is incorporating a convertible nucleoside into the 
DNA, then employing site-directed mutagenesis to introduce a cysteine residue in the protein 
(Figure 2.9).  The technique has some drawbacks, mainly the need for a researcher to have some 
knowledge of the interaction before beginning.  However, if that is known, convertible 
nucleosides for guanosine, cytosine, adenosine(MacMillan & Verdine, 1991; Xu et al, 1992) are 
available (Glen Research, TriLink Biotechnologies) and easily added into an growing DNA 
sequence with no to changes standard protocols and without destroying the hydrogen bonding 
network in the double stranded DNA(Verdine & Norman, 2003).  Typically, yields for this type of 
crosslinking exceed 80% and purification of crosslinked products is straightforward since the 
disulfide can be stably formed at pH 8 – 8.5.  Also, while disfulfides are stable, the bond is also 
46 
 
kinetically labile at pH 8.5 and will resist forming constrained conformers at this pH (Verdine & 
Norman, 2003).  This technique has been successfully used to solve the structure of HIV reverse 
transcriptase bound to an RNA primer(Huang et al, 1998), the protein GCN4 bound to 
DNA(Ellenberger et al, 1992), and a p53DBD dimer bound to DNA(Ho et al, 2006).  If base 
crosslinking is not feasible, chemistry has also recently been published demonstrating that 
crosslinkers can also be added to the backbone of DNA (Banerjee et al, 2006). 
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Figure 2.9: Schematic crosslinking representation.  The protein, represented as the gold 
cyclinder, bears a cysteine residue that comes close to the DNA. The DNA, represented as a 
cytosine (black) and modified guanosine (green), has a sulfur-bearing linker on the guanosine.  
The two should come reasonably close together when bound correctly and allow a disulfide to 
form between the linker on the guanosine and the cysteine from the protein.  This figure is 
adapted from (Verdine & Norman, 2003). 
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2.1.4. Previously solved p53DBD structures: 2GEQ, 2AC0, 2ADY, 2AHI, 2ATA 
 
In their 2006 paper, Ho et al. reported the structure of mouse p53DBD dimer bound to a 
DNA half site after creating a crosslink between the each p53DBD and its quarter site.  The 
structure, in addition to highlighting the residues necessary for p53DBD dimerization, also 
identified a third hotspot for cancerous mutations within domain and created a model 
tetrameric p53DBD bound to a full consensus site(Ho et al, 2006). 
Each p53DBD in the structure (PDB code 2GEQ) binds to its quarter site in a nearly 
symmetrical fashion across the DNA (Figure 2.10).  Cα RMSDs between each subunit of the dimer 
and the original 1TSR p53DBD is ≤ 0.748 Å, implying high structural similarity between all the 
domains.  The DNA contacts of each subunit with its pentamer sequence are also essentially the 
same as reported by Cho et al.  In this structure, the DNA half site also has a 20° bend, which is 
not seen in 1TSR(Ho et al, 2006). 
Dimerization occurs via the H1 helix and L3 loop.  Several conserved residues make 
important contacts with opposing subunits to create the dimerization interface.  Interestingly, 
mutations in these residues are found in tumor-derived p53 genes, underscoring the importance 
of dimerization to p53 function.  Along with domain stabilization, DNA contacts, and Zn2+ 
ligation, dimerization residues now represent a third hotspot for p53 mutations that lead to 
inactive proteins that are associated with human cancers (Figure 2.11)(Ho et al, 2006). 
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Figure 2.10: Structure of mouse p53DBD dimer bound to DNA, 2GEQ.  Two representations of 
the mouse p53DBD dimer are shown.  One subunit is represented in blue while the other is 
represented in green.  The consensus sequence half site is shown in grey while flanking bases 
necessary for crystallization are in red.  The Zn2+ ions are represented as yellow spheres.  The 
right-hand view is a 90° turn into the page from the left-hand view. 
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Figure 2.11: p53DBD cancer-derived mutation histogram.  The core domain amino acid 
sequences and known secondary structure for both mouse and human proteins are shown.  The 
black bar above each amino acid represents how often the particular residue is found mutated 
in human cancers.  The colored circles below certain residues represent the amino acid’s 
importance: blue = domain stability, orange = Zn2+ ligation, green = DNA contact, red = 
dimerization, yellow = residues proposed to be involved in tetramerization.  This figure is 
adapted from (Ho et al, 2006). 
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Logically, the question of whether the crosslink disrupted natural binding of each p53DBD 
subunit to the DNA must be addressed.  As stated above, the overall structure of each domain 
and its contacts to the DNA remain unchanged as compared with previous uncrosslinked 
structures.  Also, a 2Fo – Fc map contoured to 1.25 σ shows discontinuous density between the 
Cys274 (Cys277 in human numbering) and the crosslinked cytosine (Figure 2.12).  The distance 
between the sulfur of the Cys274 and N4 of the cytosine is approximately 4 Å while the full linker 
is 7.5 Å(Huang et al, 1998).  These observations lead to the conclusion that the linker remains 
flexible, in a disordered conformation and not significantly perturbing the natural binding of the 
domains to the DNA(Ho et al, 2006). 
The final part of Ho et al.’s assessment of their structure was to model a p53 tetramer 
bound to its full consensus site (Figure 2.13).  Dimer-dimer interactions were predicted to 
involve the S7-S8 loop of one subunit with the L2 loop of another(Ho et al, 2006).  In addition, 
the DNA was also predicted to bend by as much as 40°(Ho et al, 2006), which is a conclusion that 
is also supported by several solution studies(Nagaich et al, 1997a; Nagaich et al, 1999; Pan & 
Nussinov, 2007). 
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Figure 2.12: Electron densitry map in the area of the crosslink, 2GEQ.  A close up view of the 
area surrounding Cys274 (Cys277 in human numbering) is shown.  The electron density map is 
represented as green mesh and contoured to 1.25 σ.  Connected density between the sulfur of 
Cys274 and N4 of the cytosine is not seen.  This figure is adapted from (Ho et al, 2006). 
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Figure 2.13: Proposed p53DBD tetramer bound to DNA model.  The structure of the mouse 
p53DBD dimer bound to DNA (2GEQ) is shown in the left panel on the left-hand side of the 
tetramer with gray DNA.  Following the bend in the DNA, the next dimer, with the exact same 
structure, was modeled next to it to extrapolate what the full tetramer would look like.  The 
right-hand picture is obtained by rotating the left-hand picture 90° into the page, then a 90° 
rotation to the right.  This figure is adapted from (Ho et al, 2006). 
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Shortly after the publication of the kinetically trapped dimer structure, Shakked and 
colleagues published four structures (2AC0, 2ATA, 2AHI, 2ADY) of uncrosslinked human p53DBD 
dimers bound to DNA that pack together in their crystal lattices as tetramers(Kitayner et al, 
2006).  Again, the subunits in each structure have high structural similarity to the previously 
solved domains and the DNA contacts were essentially as previously reported.  The dimerization 
also occurs largely as reported by Ho et al. with a few minor differences(Kitayner et al, 2006). 
Each tetramer reported its own unique dimer-dimer interfaces (Figure 2.14).  Interestingly, 
Ser166, Glu198, Gln167 (Ser163, Glu195, and Gln164 in mouse numbering) are involved in 
dimer-dimer contacts in each tetramer, but mediate different contacts (Kitayner et al, 2006). 
 Examination of the DNA duplexes shows that they are slightly out of register with each 
other in the Kitayner et al. tetramers(Kitayner et al, 2006) (Figure 2.15), meaning that a p53DBD 
tetramer bound to a full consensus site still had not been solved and remained an open area of 
interest to the p53 community. 
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Figure 2.14: Structure of human p53DBD tetramer bound to DNA, 2AC0.  The human p53DBD 
tetramer is represented as two colored dimers.  The front dimer and DNA are colored in green 
while the back dimer and DNA are colored in blue.  Zn2+ ions are represented as yellow spheres.  
The view is looking down the DNA axis of the green dimer.  The rotation between the green 
dimer and the blue dimer is ~ 33°.  Four similar structures were published (2AC0, 2ADY, 2ATA, 
and 2AHI).   
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Figure 2.15: DNA of 2AC0.  The tetramer from Figure 2.14 is represented after a 90° rotation out 
of the page.  The A-B dimer is shown in light green while the C-D dimer is shown in dark green.  
The half sites bound by each dimer are shown in blue.  The DNA axis for the A-B dimer is out of 
register from the C-D dimer.  Another picture of this can be seen in Figure 2.35, as well.  This 
figure is adapted from (Kitayner et al, 2006). 
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2.2.   Materials and Methods 
 
2.2.1. Growth and purification of mouse p53DBD 
 
Residues 98 – 292 of mouse p53 were cloned into the pRSETa vector (Invitrogen) such that it 
had no tag.  DE3 Escherichia coli (E. coli) cells were transformed with the plasmid, grown in the 
presence of 100 µg/mL amipicillin, and induced with 1 mM isopropyl ß-D-1-
thiogalactopyranoside (IPTG) and 10 µM Zn(OAc)2 overnight at 15°C.   
Cell pellets were resuspended in 20 mM citrate pH 6.1, 100 mM NaCl, 10 µM Zn(OAc)2, 1 
mM tris(2-carboxyethyl) phosphine hydrochloride (TCEP), and 10 µg/mL phenylmethanesulfonyl 
fluoride (PMSF).  Cells were lysed by sonication at 4 °C and the insoluble fraction was separated 
by centrifugation at 18,000 rpm (SS-34 rotor, Sorvall) for 30 minutes.  The soluble fraction was 
passed over pre-equilibrated SP sepharose resin (GE Healthcare), washed and eluted on an NaCl 
gradient of 100 mM – 1 M. 
The cleanest fractions were pooled, concentrated and run over a Superdex 75 preparative 
gel filtration column (Amersham Biosciences), where p53DBD eluted as a monomer (Figure 
2.16).  Peak fractions from the column were pooled and concentrated to at least 5 mg/mL 
before flash freezing on dry ice and long term storage at - 80°C. 
The p53DBD point mutant T281C was prepared by standard mutagenesis and purified in the 
same manner.   
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Figure 2.16: Gel filtration of p53DBD.  Representative superdex 75 gel filtration chromatogram 
for p53DBD purification is shown.  The protein peaks just before the 17 kDa standard, which fits 
for a monomeric, 22 kDa protein.  The 15% SDS-PAGE gel insert shows that the six fractions of 
the peak are pure p53DBD. 
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2.2.2. Synthesis and purification of DNA containing unnatural nucleotides 
 
 
2.2.2.1. Base crosslinking DNA strands 
 
DNA oligonucleotides containing the unnatural 04-triazolyl-2’-deoxyuridine base were 
ordered from TriLink Biotechnologies (San Diego, CA) or synthesized on the Applied Biosystems 
DNA Synthesizer 394.  DNA strands, capped with a 5’-dimethoxy-trityl group (trityl), were 
shipped on the resin with standard protecting groups on all bases following the synthesis. 
Resin was incubated with 1 mL of 0.5 M cystamine (Sigma), pH 12 and placed on a shaker for 
two hours to cleave DNA strands from the resin.  Samples were spun at maximum speed for 10 
minutes to pellet the resin and the supernatant was removed.  Cleaved DNA strands were 
placed in a 55°C heat block overnight for complete deprotection of all nucleotides and 
cystamine replacement of the triazolyl group. 
Following dialysis with Spectrapor 2000 MWCO tubing (Spectrum Laboratories) into water 
and lyophilization, DNA strands were resuspended in 500 µL deionized water.  Further 
purification was performed by reverse-phase HPLC to separate the failure sequences via the 5’-
trityl, which was subsequently removed from correct sequences after treatment with 
trifluoroacetic acid (TFA). 
Strands were dialyzed into water once more, lyophilized and dissolved in ~ 40 µL of water.  
DNA concentrations were determined by UV absorbance and strand composition was confirmed 
by matrix assisted laser desorption ionization (MALDI) time of flight (TOF) mass spectrometry 
(Figure 2.17). 
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Figure 2.17: Scheme for creating DNA capable of base crosslinking.  The left-hand side shows 
DNA as synthesized, complete with all protecting groups.  The right-hand side shows the DNA 
when fully deprotected, purified, and ready for use. 
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2.2.2.2. Backbone crosslinking DNA strands 
 
Cystamine free base was prepared from cystamine-HCl (Sigma) by neutralization with 
sodium hydroxide and subsequent extraction with dichloromethane.   
DNA oligonucleotides were alternately synthesized on the Applied Biosystems DNA 
Synthesizer 394 and by hand.  All reagents and phosphoramidites were ordered from Glen 
Research (Sterling, VA) unless otherwise stated.  Backbone modification occurred between two 
nucleotides on the growing stand so automated synthesis was stopped at the base 3’ to the 
phosphate group modification after trityl removal.  Columns were removed from the 
synthesizer, flushed with 50:50 acetonitrile:pyridine, and incubated with H-phosphonate plus 1-
adamante carbonylchloride (activator) for one hour.  Columns were then washed, and DNA 
backbones were oxidized with cystamine free base dissolved in carbon tetrachloride (Sigma) for 
one hour.  Failure sequences were then capped with isopropyl phosphate and columns were 
washed with 50:50 acetonitrile:pyridine followed by 100% acetonitrile(Banerjee et al, 2006).  
Columns were placed back on the synthesizer, where the remaining nucleotides were added to 
the growing strands with the standard Applied Biosystems 1 µM DNA synthesis protocol (Figure 
2.18). 
To make DNA with only backbone crosslinking: Following synthesis, DNA strands were 
cleaved from the resin and deprotected in ammonium hydroxide before HPLC purification. 
To make DNA with mixed crosslinking: Following synthesis, purification of DNA was carried 
out the same as base crosslinking strands. 
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Figure 2.18: Scheme for creating DNA capable of backbone crosslinking.  The left-hand side 
shows DNA as was synthesized, complete with all protecting groups.  The right-hand side shows 
the DNA when fully deprotected, purified, and ready for use. 
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2.2.3. Purification of crosslinked tetramers 
 
Crosslinking was performed the same for all types of modified strands: base crosslinking 
with p53DBD, backbone crosslinking with p53DBD T281C, mixed crosslinking with p53DBD 
T281C (Figure 2.19, Figure 2.20).   At room temperature in 20 mM citrate, pH 6.1, 100 mM NaCl, 
and 0.5 mM TCEP, a 4:1 molar ratio of p53DBD to DNA was added to excess buffer and allowed 
to sit for three hours at room temperature. The crosslinking reaction was loaded onto Q resin 
(GE Healthcare) and higher order oligomers were eluted with a gradient of 100 mM to 500 mM 
NaCl.  Tetrameric complexes eluted first since its negative charges were the least available for 
binding with the resin.  Denaturing but non-reducing gels were run to assay purity.  Tetramer 
purity was determined by the presence of only one band corresponding to one strand of DNA 
with two bound p53DBDs.  These fractions were pooled and concentrated to 5 μM as 
determined by a standard curve of known protein-DNA concentrations and frozen at –80°C until 
use. 
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Figure 2.19: Purification of p53DBD tetramer by base crosslinking.  Following incubation of a 
4:1 molar ratio p53DBD:DNA, samples were run over pre-equilibrated Q resin and eluted on an 
NaCl gradient of 100 – 500 mM.  The first three lanes of this 15% denaturing, but non-reducing 
gel show p53DBD alone, crosslinking reaction before loading onto Q resin, and flow through 
from the Q resin.   The crosslinking reaction clearly shows three bands: lowest band is p53DBD 
alone (22 kDa), middle band is one p53DBD + one DNA strand (22 kDa + 7 kDa = 29 kDa), the 
highest band is two p53DBD + one DNA strand (7 kDa + 44 kDa = 51 kDa).  The next several lanes 
all represent fractions of the elution.  Fractions that only showed upper band were concluded to 
contain DNA crosslinked to four p53DBD subunits.  These fractions were pooled and 
concentrated for crystallization. 
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Figure 2.20: Samples of p53 tetramer by backbone crosslinking.  Following incubation of a 4:1 
molar ratio p53DBD T281C:DNA, samples were run over pre-equilibrated Q resin and eluted on 
an NaCl gradient of 100 – 500 mM.  The first lane of this 15% denaturing, but non-reducing gel 
shows p53DBD T281C alone (22 kDa).  The next several lanes show crosslinking reactions under 
various buffer conditions and pH with the same molecular weights as described in Figure 2.19.  
The crosslinking reactions clearly show three bands: lowest band is p53DBD T281C alone (22 
kDa), middle band is one p53DBD T281C + one DNA strand (22 kDa + 7 kDa = 29 kDa), the 
highest band is two p53DBD T281C + one DNA strand (7 kDa + 44 kDa = 51 kDa). 
 
 
 
 
 
66 
 
2.2.4. Crystallization, data collection and refinement of base crosslinked tetramers 
 
Crystals of base crosslinking tetramers were grown in 200 mM lithium citrate, 20% PEG 3350 
by hanging drop vapor diffusion.  Small, rectangular crystals appeared in two days and reached a 
maximum size of 160 x 30 x 30 uM after one week (Figure 2.21).  Crystals were frozen in the well 
condition with 15 - 20% glycerol.  Data collection was carried out on the 23-IDB beamline at the 
Advanced Photon Source synchrotron at Argonne National Laboratories.   Data was indexed and 
scaled using HKL2000 (Otwinowski & Minor, 1997).  During indexing, it was found that tetramers 
packed one of two ways, which yielded two different unit cells and subsequently two tetramer 
structures.  The structures were solved by molecular replacement using PHASER with 2GEQ as a 
search model.  For structure 1, the resulting solution was the p53DBD dimer bound to its half 
site in an asymmetric unit cell with a full tetramer containing a crystallographic two-fold axis.  
For structure 2, the resulting solution was the p53DBD monomer bound to its quarter site in an 
asymmetric unit.  These models were refined in CNS using simulated annealing, minimization 
and individual B-factor refinement.  For structure 1, medium NCS restraints were initially used 
for the two p53DBD domains in the asymmetric unit.  The NCS restraints were gradually lowered 
and were eventually dropped completely.  Between refinement cycles, the model was manually 
rebuilt using the program Coot(Emsley & Cowtan, 2004).  Data collection and refinement 
statistics for structures 1 and 2 are summarized in Table 2.1. 
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Figure 2.21: Crystals of p53DBD tetramers with base crosslinking.  These crystals were 
grown in 200 mM lithium citrate, 20% PEG 3350 by hanging drop vapor diffusion and were 
harvested, frozen and collected upon as described in the text. 
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Table 1.  Crystallographic statistics for base crosslinked tetramers.  Tetramers packed in two 
different ways to form crystals.  These differences in packing will be discussed in Section 2.3.1.  
Crystallograhic statistics are provided for both crystal packing forms. 
a: Rsym =  ΣhΣl |Ihj – Ih| / ΣhΣh,i, where Ih is the mean intensity of symmetry-related reflections. 
b: Rwork = Σ ||Fo| - |Fc|| / Σ |Fo|, Fo is observed structure factor amplitudes; Fc is calculated 
structure factor amplitudes. 
c: Rfree is calculated from the withheld 5% of data. 
This table is adapted from (Malecka et al, 2009). 
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2.2.5. Crystallization of backbone crosslinked and mixed crosslinking tetramers 
Crystals of backbone crosslinked tetramers (all four subunits crosslinked via the DNA 
backbone) were grown in 200 mM potassium sulfate, 20% PEG 3350 (Figure 2.22).  Crystals of 
tetramers with mixed crosslinking (two subunits crosslinked via Cys274, two subunits via the 
DNA backbone) were grown in 200 mM zinc acetate dehydrate, 20% PEG 3350 (Figure 2.23) by 
hanging drop vapor diffusion.   The former crystals appeared after one night while the shower of 
small crystals (≤ 30 µM3) in the latter took at least one month to grow.  The latter crystals were 
frozen in 200 mM zinc acetate, 20% PEG 3350, 20 – 25% glycerol, but yielded no diffraction. 
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Figure 2.22: Crystals of backbone crosslinked tetramers.  These crystals were prepared with all 
four individual subunits crosslinked to the backbone of the consensus sequence DNA and grown 
in 200 mM potassium sulfate, 20% PEG 3350 by hanging drop vapor diffusion.  They appeared 
overnight.  See Figure 2.40 for the DNA seqeuence. 
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Figure 2.23: Crystals of mixed crosslinked tetramers.  These crystals were prepared by mixing 
base crosslinking and backbone crosslinking.  Two subunits are crosslinked via Cys274 while two 
subunits are crosslinked to the backbone of the DNA.  They were grown in 200 mM zinc acetate 
dehydrate, 20% PEG 3350 by hanging drop vapor diffusion and took at least 1 month to grow.  
See Figure 2.41 for DNA sequence. 
 
 
 
 
 
 
 
72 
 
2.3.   Results and Discussion 
 
 
2.3.1. Crystal Structure of p53DBD tetramer bound to DNA 
 
Two tetrameric p53DBD/DNA complex structures, referred to as structure 1 (PDB code 3EXJ) 
and structure 2 (PDB code 3EXL), were determined to resolutions of 2.00 and 2.20 Å respectively 
(Table 2.1).  Both structures contain the same DNA duplex (Figure 2.24, Figure 2.25) and the 
same crosslinks, but structure 1 shows ordered density for the entire 23 basepairs while only the 
central 20 base pair consensus sequence can be modeled in structure 2.  Both protein/DNA 
complexes crystallized in spacegroup C2, but the cell parameters and asymmetric units of these 
complexes differ, with structure 1 containing a p53DBD dimer bound to a DNA half site and 
structure 2 containing a p53DBD subunit bound to a DNA quarter site.  As a result of these 
differences, the crystal packing contacts show significant differences between the two 
structures.  The most significant difference lies along the direction of the DNA helical axis.  The 
DNA in structure 1 forms end-end Hoogsteen base-pairs involving the overhanging 5’ thymine 
base of one DNA duplex with the Watson-Crick base-paired adenine of another duplex (Figure 
2.26).  In contrast, the DNA duplex in structure 2 does not show electron density for the 
overhanging 5’ thymine base or the adjacent adenine-thymine base pair, which are presumably 
looped out of the DNA helix.  As a result of this, two adjacent DNA duplexes of structure 2 stack 
end-to-end forming a pseudo continuous helix with the terminal DNA base-pairs from adjacent 
DNA duplexes about 3.6 Å apart (Figure 2.26).  The shorter ordered DNA duplex within structure 
2 relative to structure 1 results in more extensive protein contacts between adjacent p53DBD 
tetramer/DNA complexes within the crystal lattice of structure 2 relative to structure 1 (Figure 
2.27).  Despite these crystal packing differences between structure 1 and 2, the overall 
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structures of the p53DBD tetramer/DNA complexes are essentially superimposable in the two 
crystal lattices (Figure 2.27), arguing that the solved tetramer structures reported here are 
biologically relevant (Rhodes, 2000, pgs 34 - 35).  Unless otherwise stated, discussion will focus 
on the higher resolution structure 1. 
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Figure 2.24: DNA used for crystallization and view of crosslink.  The consensus sequence is 
boxed and crosslinked bases are in red.  This figure is adapted from (Malecka et al, 2009). 
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Figure 2.25: MALDI chromatogram for DNA used in p53DBD tetramer crystallization.  The 
major observed peak is 7314.1 Da while the calculated mass of the DNA duplex is 7310.1 Da. 
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Figure 2.26: Crystal packing of DNA 5’ and 3’ ends in structures 1 and 2.  View of DNA base 
pairing between crystallographic DNA duplexes in structures 1 and 2 with involved bases 
numbered as in Figure 2.25.  One duplex is colored green and the crystallographic duplex is 
colored in blue.  Hydrogen bonds are depicted in orange.  This figure is adapted from (Malecka 
et al, 2009). 
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Figure 2.27: Crystal packing of both structures 1 and 2.  View of tetramer crystal packing in 
both structures 1 and 2.  Structure 1 is colored in red and structure 2 is colored in gray.  A 
tetramer is shown for both structures with a dimer from the adjacent crystallographic 
tetramer shown to the right.  A clear gap is seen between structure 1 and its crystallographic 
dimer neighbor while no such gap is seen for structure 2.  This figure is adapted from 
(Malecka et al, 2009). 
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2.3.2. Structure of each p53DBD within the tetramer and DNA contacts 
 
Within the tetramer, the structure of each of the p53DBD subunits is nearly identical to each 
other (Cα rmsd ≤ 0.105 Å) and to other p53DBD domain structures that have been determined 
(Cα rmsd ≤ 0.559 Å)(Cho et al, 1994; Wang et al, 2007; Zhao et al, 2001).  Briefly, each domain is 
comprised of two anti-parallel β sheets that form an immunoglobulin-like β sandwich.  Each 
strand is twisted resulting in two very different ends of the sandwich; one end is compact with 
short loops while the other end splays to the loop-sheet-helix motif, which contains a 
tetrahedrally bound Zn2+ ion, the L2 loop, and the H2 α helix (Figure 2.28).   
The major difference between each tetramer subunit and the previous structures lies within 
the L1 loop, residues 109 – 119 (Figure 2.29).  Both Cho et al. (human p53DBD monomer bound 
to DNA) and Kitayner et al. (human p53DBD dimer of dimers bound to a discontinuous DNA 
duplex) stress the importance of the L1 loop for DNA recognition since Lys120 (Lys117 in mouse) 
at the loop’s tip points into the major groove to make a base-specific DNA contact(Cho et al, 
1994; Kitayner et al, 2006).  In contrast, here Lys117 and the L1 loop in each subunit has moved 
nearly 15 Å away from the DNA and adopts some α helical structure.  
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Figure 2.28: Structure of the tetrameric p53DBD/DNA complex.  Upper and lower panels show 
the overall view of the tetramer in cartoon representation.  Subunits A (blue) and B (cyan) 
represent one dimer and subunits C (purple) and D (pink) represent the other.  Zn2+ ions are 
shown as yellow spheres.  The DNA consensus sequence is rendered in red and other bases are 
rendered in gray.  The lower panel is a 90° turn into the page followed by a 90° turn to the right 
of the upper panel.  This figure is adapted from (Malecka et al, 2009). 
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Figure 2.29: The L1 loops from several previously solved p53DBD structures.  A close up view of 
the L1 loops from human (2OCJ, orange), and mouse (1HU8, red) p53BD; human p53DBD (1TSR, 
yellow), human p53DBD dimer (2AC0, magenta), mouse p53DBD dimer (2GEQ, cyan), bound to 
DNA; Cep-1 p53 ortholog (1T4W, blue), mouse p53DBD tetramer bound to DNA structure 1 
(green) and structure 2 (light green).  This figure is adapted from (Malecka et al, 2009). 
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The DNA contacts made by each subunit to the DNA are essentially as reported by Cho et 
al.(Cho et al, 1994).  Three minor variations, which are also observed in the other p53DBD/DNA 
structures, are seen in each subunit.  First, Lys117 (Lys120 in human p53) of the L1 loop has 
moved away from the DNA and towards the tetramerization interface as previously described in 
subunits B and D of structure 1 and all subunits of structure 2 (Figures 2.29, Figure 2.32, and 
Figure 2.33).  In subunits A and C of structure 1, this residue is disordered.  Second, Arg280 
(Arg283 in human p53), part of the H2 helix, is too far to contact the phosphate backbone.  
Third, Arg245 (Arg248 in human p53), the most frequently mutated residue in human cancers, 
adopts two different conformations in structure 1 and its DNA contact changes accordingly.  In 
structure 2 and subunits A and C of structure 1, Arg245 sits in the minor groove and contacts the 
DNA as reported in Cho et al.  However, in subunits B and D of structure 1, the same residue 
adopts a 90º bend and only contacts the backbone of one DNA strand.  Taken together, analysis 
of the protein/DNA contacts within the tetrameric p53DBD bound to DNA reveals that the basic 
residues 117, 245 and 280 have variable roles in DNA recognition. 
 
2.3.3. Structures of each p53DBD dimer and tethers 
 
Each dimer (A-B and C-D, Figure 2.28) within the tetramer comes together as previously 
described by Shakked and coworkers for 2AC0 (Kitayner et al, 2006).  Key residues involved are 
Arg178, Pro174, His175, Gly241 and Met243.  Also, the dimers show little structural variation 
from the previously reported mouse p53DBD dimer (Cα rmsd 0.776 Å(Ho et al, 2006)). 
Each p53DBD subunit is tethered to its quarter site via the side chain sulfur of Cys274 to the 
modified sulfur-bearing linker attached to the N4 atom of the cytosine 3’ to the invariant 
82 
 
guanine (Figure 2.24).  The extended tether has a length of 7.5 Å(Huang et al, 1998).  Figure 2.30 
shows simulated annealing composite omit maps for each p53DBD/DNA complex structure 
around residue Cys274.  Structure 2 clearly shows a break in density, strongly indicating that the 
linking atoms are not rigid.  Structure 1 shows connected density between the atoms but it lacks 
defined structure also supporting the tether’s flexibility.  The distance between the crosslinked 
atoms is less than 4.1 Å and nearly all the DNA contacts previously reported are intact 
suggesting that the tether is flexible and does not perturb the p53/DNA interface.   
Taken together, the similarity of p53DBD-DNA interactions reported here to the DNA 
interactions with the monomeric p53DBD(Cho et al, 1994; Wang et al, 2007; Zhao et al, 2001) 
and dimeric p53DBD (Ho et al, 2006; Kitayner et al, 2006), and the lack of rigid tether density in 
the structures reported here, these data support the conclusion that the tether does not 
significantly disrupt the natural binding properties of the p53DBD to its consensus site. 
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Figure 2.30: View of the electron density at the crosslink.  Simulated annealing composite 
omit 2Fo-Fc map contoured at 1.0 σ (left) and 1.3 σ (right) at the area of crosslinking.  DNA 
consensus sequence atoms are colored in red.  Protein atoms are colored in green (structure 
1, left) or light green (structure 2, right).  This figure was adapted from (Malecka et al, 2009). 
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2.3.4. Structure of the p53DBD tetramer and dimer-dimer contacts 
 
The p53DBD tetramer binds to its DNA consensus sequence as a dimer-of-dimers as 
previously proposed (Figure 2.28).  Each dimer (A-B and C-D) binds to its respective half site with 
no relative twist and without significant DNA bending (Figure 2.28, Figure 2.31).  Each dimer-
dimer interface buries an average of 665 Å2 of surface area and shows nearly the same 
interactions in each structure.  The major interface involves the L2 loop from subunits A and C 
tucking against the S2’/S3, S5/S6 and S7/S8 loops from subunits B and D (Figure 2.31) and is 
stabilized by both van der Waals forces and a network of hydrogen bonds (Figures 2.32, Figure 
2.33).  The backbone nitrogen of D-Ala135 (S2’/S3) donates a hydrogen bond to A-Gln164 OE1 
(L2), which in turn accepts a hydrogen bond from the side chain hydroxyl of D-Thr137 (S3).   This 
hydroxyl also accepts a hydrogen bond from the side chain of A-Ser163 (L2).   D-Gln164 NE2 also 
donates a hydrogen bond to the backbone oxygen of D-Ala135, while the side chain of A-Thr167 
(L2) donates a hydrogen bond to OE1 of D-Glu195 (S5/S6).  Completing this major contact region 
are two van der Waals interactions: D-His230 CE1 (S8) with A-Ser163 CB and D-His230 CD2 with 
A-Met166 CE (L2).  In structure 2 (Figure 2.33), the van der Waals contact involving A-Met166 CE 
is lost due to a different side chain conformation, but an additional hydrogen bond is present 
between D-His230 ND1 and the side chain of A-Ser163. 
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Figure 2.31: p53DBD dimer-dimer formation.  View of subunit A (blue) and D (magenta) in 
surface representation for structure 1.  Subunits B and C have been removed for clarity.  This 
figure was adapted from (Malecka et al, 2009). 
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Figure 2.32: Interactions at dimer-dimer interface for structure 1.  Overall view (left) and close 
up view (right) of the dimer-dimer interaction between subunits A and D for structure 1.  
Hydrogen bonds are depicted as orange dashed lines.  The same interactions are seen between 
subunits B and C.  This figure was adapted from (Malecka et al, 2009). 
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Figure 2.33: Interactions at dimer-dimer interface for structure 2.  Overall view (left) and close 
up view (right) of the dimer-dimer interaction between subunits A and D for structure 2.  
Hydrogen bonds are depicted as orange dashed lines.  The same interactions are seen between 
subunits B and C.  This figure was adapted from (Malecka et al, 2009). 
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Both structures 1 and 2 show that D-Tyr199 (S5/S6) donates a hydrogen bond to AGln207 
(S6/S7) near the top of each interface.  Structure 2 has one additional hydrogen bond between 
D-Glu221 (S7/S8) and the backbone nitrogen of A-Lys98 (modeled as alanine in the structure).  
Overall, both structures have very similar dimer-dimer interfaces and involve nearly the same 
residues.   
A sequence alignment of all p53DBD sequences available(Gasteiger et al, 2003) underscores 
the importance of these dimer-dimer interacting residues.  Glu195 and Ala135 are strictly 
conserved, while Thr137 is strictly conserved in all species except chicken.  Also, Gln207, Gln164 
and Glu221 only show conservative mutations.  This described interface is also consistent with 
previous studies implicating specific residues for dimer-dimer interactions (Cho et al, 1994; Ho 
et al, 2006; McClure & Lee, 1998; Pan & Nussinov, 2007; Pan & Nussinov, 2008)  The most often 
sited tetramerization residues implicated for such interactions include Ser93, Ser96, Thr167, 
Ser163, Gln164 from one domain and Glu195, Thr137, and Glu221 from the other.  All except for 
residues Ser93, Ser96 (disordered in these structures) and Gly196, each of the implicated dimer-
dimer contact residues are observed to make contacts at the dimer-dimer interface of the 
structures reported here.   
A curious area of the tetramerization interface involves the enigmatic Lys117 of the L1 loop.  
As previously stated, the L1 loop of each subunit has moved far from where other p53DBD and 
p53DBD/DNA structures have it placed (Figure 2.28, Figure 2.32, and Figure 2.33).  Due to this 
movement, Lys117 points up towards residues D-Thr137 and A-Ser163 but does not make any 
specific contacts with the opposite dimer.  Several possibilities exist to explain this 
conformational change.  Careful analysis around Cys274 shows that the tether can only loop in 
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one direction, which is towards the L1 loop.  In fact, the tether is likely blocking the DNA bases 
that Lys117 has previously been shown to contact.  However, the tether is only 7.5 Å in length 
and the L1 loop has moved approximately 15 Å away, which is much too far to attribute only to 
steric hindrance by the tether.  Alternatively, the current position of the L1 loop be stabilized by 
crystal contacts from a symmetry-related subunit or the presence of a citrate molecule, which 
sits close to the new conformation.  Perhaps the most intriguing possibility is that the shift in 
position is induced by tetramerization itself.  Lys117, which is strictly conserved across all 
species but shows low cancerous sensitivity(Ho et al, 2006), and although this residue is shown 
to make base specific contacts in several reported experimental p53/DNA complexes (Cho et al, 
1994; Kitayner et al, 2006; Pan & Nussinov, 2008), but it also disordered in others (Ho et al, 
2006; Kitayner et al, 2006; Pan & Nussinov, 2008).  Within structure 1, Lys117 is only ordered in 
subunits B and D, the two p53DBD subunits in the crystal lattice that allow Lys117 to come close 
to the tetramerization interface.  Lys117 is ordered in structure 2.  Zupnick and Prives studied a 
K120A (Lys117 in mouse p53DBD) mutation for its effects on p53 function.  They found that the 
mutant had strong DNA binding in vitro, but a weaker affinity in vivo.  Overexpression in cells 
resulted in normal p53 function, however upon expression at normal cellular levels, the mutant 
showed defects in transactivation and apoptosis (Zupnick & Prives, 2006).  It is interesting to 
speculate that Lys117 might alternate between DNA base contact and tetramerization contact, 
thus explaining its ambiguity.  Clearly, additional studies will have to be carried out to resolve 
the role of Lys117 in the DNA binding properties of p53.  
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2.3.5. Comparison with other p53DBD tetramers 
 
Two p53DBD tetramer complexes with DNA have been made available recently and vary in 
their structures.  Ho et al. proposed a model p53DBD tetramer bound to DNA, which was 
generated by translating their crystallographic p53DBD dimer down the DNA to the next half 
site(Ho et al, 2006).  This model predicted that the dimers come close at the L2 loop and S7/S8 
regions, which is consistent with what we see in our current structures.  A 40º DNA bend was 
also proposed in this model as well as models from Nagaich et al.(Nagaich et al, 1999) and Pan 
et al. (Pan & Nussinov, 2007).  Interestingly, the present structures reveal that the DNA is 
relatively straight.  Previous studies suggested that a straight p53DBD tetramer/DNA complex 
would not be possible due to steric clashes.  To alleviate these clashes, it was proposed that the 
DNA would have to bend by as much as 50˚(Balagurumoorthy et al, 1995; Nagaich et al, 1997a; 
Nagaich et al, 1999; Nagaich et al, 1997b; Pan & Nussinov, 2007).  In contrast to these proposals, 
the two p53DBD tetramer/DNA structures reported here clearly show that a stable tetrameric 
complex can bind to straight, B-form DNA and maintain well-ordered dimer-dimer interfaces.   
Shakked and coworkers reported on the structure of a p53DBD tetramer bound to 
discontinuous DNA where two p53DBD dimers bound to DNA came together end-to-end within 
their crystal lattices(Kitayner et al, 2006).  These dimers are twisted 33˚ relative to each other in 
each structure (Figure 2.34).  While, the two DNA half sites appear to be out of register for each 
(Figure 2.35), they can be considered approximate p53DBD tetramers and provide insight into 
alternative dimer-dimer contacts.  Each tetramer shows its own set of limited dimer-dimer 
contacts.  2AC0, 2AHI, and 2ATA are quite similar in that one dimer-dimer interface is devoid of 
interaction and the other has limited hydrogen bonds and water-mediated interactions.  2ADY is 
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unique in that both interfaces have the same five hydrogen bond interactions.  Interestingly, as 
in the p53DBD tetramer/DNA complexes reported here, Ser166, Gln167, and Thr170 (Ser163, 
Gln164 and Thr167 in mouse p53DBD) are involved in hydrogen bonds in the p53DBD 
tetramer/DNA complexes reported by Shakked and coworkers but these residues mediate 
different hydrogen bonds within the two complexes.   
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Figure 2.34: Superposition of the p53DBD tetramer with 2AC0.  The upper panel is a view down 
the helical axis of 2AC0 after superposition of the p53DBD tetramer/DNA complex.  The upper 
panel is the same except both structures have been rotated 90° into the page.  2AC0 is rendered 
in magenta and structure 1 is rendered in green.  Each p53DBD tetramer/DNA complex is shown 
separately for clarity.  The 33° twist of the back dimer relative to the front is easily seen for 
2AC0.  This figure is adapted from (Malecka et al, 2009). 
93 
 
 
 
Figure 2.35: Comparison of the DNA from the p53DBD tetramer and 2AC0.  DNA from 2AC0 
(upper), structure 1 (middle) and structure 2 (lower) as Calladine-Drew schematics.  Duplex 1 
and 2 of 2AC0 are labeled and the central helical axes are shown as dotted lines.  Duplex 1 is 
lower and rotated toward the viewer relative to duplex 1.  All schematics were made with 
3DNA(Lu & Olson, 2003) and rendered in PyMOL(DeLano, 2002).  This figure was adapted from 
(Malecka et al, 2009). 
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2.3.6. Multiple tetramerizations modes for p53 on DNA 
 
After comparison of the p53DBD tetramer/DNA models with the two complexes 
reported here, we hypothesize that dimer-dimer contacts within the p53DBD tetramer on DNA 
can vary in vivo.  This hypothesis is supported by several lines of evidence.  First, p53 response 
elements are varied across the genome due to different base-pair spacing between half sites 
and response elements which fulfill the consensus sequence requirement (El-Diery et al, 1992).  
Second, the current structure shows that the DNA need not be bent for four p53DBD domains to 
stably bind to it.  Given that solution studies and molecular dynamics suggest that bent DNA 
complexes are possible (Nagaich et al, 1999) and the inherent flexibility of the DNA sequences 
has been studied(McNamara et al, 1990; Nagaich et al, 1994; Zhurkin et al, 1991), it is likely that 
other energy minima exist besides the one captured crystallographically here.  Also, while 
several of the residues at the interface involved are conserved, cancerous mutations of the 
residues are low compared with DNA contacts or monomer-dimer contact residues within the 
p53DBD(Ho et al, 2006).  Taken together, these observations suggest that perhaps the 
tetramerization interface is not fixed, but able to accommodate different contacts depending on 
different cellular conditions. 
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2.3.7. p53 DNA binding cooperativity 
 
It has been shown that the predominantly monomeric p53DBD will bind to its consensus 
sequence DNA in a highly cooperative manner(Balagurumoorthy et al, 1995) and the basis for 
this cooperativity has been the subject of much speculation.  McClure et al. studied how 
p53DBD dimers and tetramers could bind DNA oligomers by varying the placement of the 
consensus quarter sites.  Results from this work showed that two p53DBD dimers will bind a full 
consensus site for a far longer period of time (t1/2 ~ 15 minutes) than one dimer alone (t1/2 ~ 30 
seconds)(McClure & Lee, 1998).   A similar experiment was performed with wild-type p53 
(residues 94 – 360, tetrameric) and an L344A mutant construct that could only form dimers.  The 
results showed that tetramers had a six-fold greater affinity for DNA over dimers (Weinberg et 
al, 2004).  Correlating this data with the two structures reported here suggests that two dimers 
are more stably bound to DNA due to the numerous dimer-dimer contacts that are observed in 
the structures reported here.  One dimer bound to DNA benefits from both stabilizing DNA and 
dimerization contacts (Klein et al, 2001), but according to McClure et al and supported by 
Weinberg et al, will still diffuse away from the DNA in a short period of time.  With the added 
dimerization contacts, the complex is more stable, as evidenced by the increase in t1/2 and 
affinity.   
Other suggestions have been reported for p53DBD cooperativity but are not supported by 
crystal structures(McClure & Lee, 1998).  No conformational change is seen within the p53DBD 
upon tetramerization or DNA binding.  While it is possible that other areas of the protein may 
undergo structural rearrangement during DNA binding, cooperativity is seen at the level of 
p53DBD binding to DNA alone, thus implicating determinants for DNA-binding cooperativity 
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within the DNA-binding domain of p53.  Also, cooperative DNA binding by p53 is largely 
influenced by its tetramerization domain in vivo.  Taking these observations together with the 
p53DBD tetramer/DNA complexes reported here suggests the DNA-induced interactions that 
are observed between the two p53DBD dimers plays a major role in cooperative p53DBD 
binding to DNA. 
 
 
2.3.8. p53DBD conservation and implication for function 
 
 
A surface conservation map of the p53DBD in the context of the p53DBD tetramer bound to 
DNA reveals several areas of high conservation and by inference functional importance.  The 
highest degree of conservation maps to the DNA binding region of the monomer and the 
monomer-dimer interface (Figure 2.36) highlighting the relative importance of these regions.  In 
contrast, the dimer-dimer interface shows far less conservation (Figure 2.37) arguing for a less 
significant role of p53DBD dimer-dimer contacts for DNA recognition.  Subunit A shows a long 
groove of conservation that is set back from the L2 loop.  A mirrored pattern on subunit B would 
suggest a strict dimer-dimer interaction, but this is not seen and further supports the model that 
multiple tetramerization modes can accommodate p53 binding to DNA.  
 Intriguingly, a comparison of subunit A and B shows that one side of each subunit is more 
conserved than the other (Figure 2.37).  For subunits B and D, this highly conserved surface 
would face the solvent rather than the opposite dimer.  It is possible that these residues 
participate in binding other domains of p53 or partner proteins of p53.  This could also be the 
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case for the ring of conserved amino acids that map around the back surface of each subunit 
(Figure 2.38).  Taken together, the sequence conservation on the surface to the p53DBD 
tetramer bound to DNA suggests other protein binding and perhaps regulatory surfaces. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
 
 
Figure 2.36: Surface map showing the most highly conserved regions of p53DBD.  A sequence 
alignment was performed with all known sequences of p53 using ClustalW(Gasteiger et al, 2003) 
and mapped with ESPript(Gouet et al, 1999).  View of subunits A and D with strictly conserved 
residues colored in red and nonconserved residues colored in blue.  The DNA is rendered in 
gray.  Subunits B and C have been removed for clarity.   This figure was adapted from (Malecka 
et al, 2009). 
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Figure 2.37: Surface map showing the dimer-dimer interface p53DBD tetramerization.  The 
same techniques were used here as in Figure 2.37.  This is a view along the DNA helical axis of 
subuits A and B.  Subunits C and D have been removed for clarity.  The dimer-dimer interface is 
circled with a black line.  This figure was adapted from (Malecka et al, 2009). 
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Figure 2.38: Surface map showing the back of the dimer-dimer interface.  The same techniques 
were used here as in Figure 2.37.  This is the same orientation as Figure 2.37, but focusing on 
the back of the subunits.  The band of conserved residues is notable.  This figure was adapted 
from (Malecka et al, 2009). 
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2.3.9. Backbone crosslinking and mixed crosslinking results 
 
As previously discussed, the L1 loop is an intriguing area of the p53DBD (Figure 2.29).  Some 
structures, such as the original human p53DBD(Cho et al, 1994) bound to DNA and some of 
Kitayner et al’s tetramers(Kitayner et al, 2006), show Lys120 pointing into the major groove and 
making a specific contact.  Other structures, such as the mouse p53DBD dimer structure(Ho et 
al, 2006), the mouse tetramer structures reported here, and some of Kitayner et al’s 
structures(Kitayner et al, 2006), Lys120 or the entire L1 loop is disordered. 
In 3EXJ and 3EXL, the distance between the sulfur of Cys274 and N4 of the cytosine is ~ 4 Å 
and the entire linker is 7.5 Å so the rest of the linker must loop out (Figure 2.30).  Careful 
analysis of the area surrounding Cys274 shows that the extra linker is potentially covering the 
purines Lys120 has been reported to contact.  However, the L1 loop has moved nearly 15 Å 
away in response, which is much too far to attribute to the linker alone.   
Curious to know if this movement was due to tetramerization or linker, we set about moving 
the crosslink away from the L1 loop.  Base crosslinking was not possible anywhere else in the 
structure, but backbone crosslinking, which had recently been described by Verdine and 
colleagues(Banerjee et al, 2006), was a good option.  Thr281 came within 4 Å of the phosphate 
backbone between the invariant cytosine and 3’ adenosine so, by use of site-directed 
mutagenesis, became Cys281 (Figure 2.39).   
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Figure 2.39: Close up view of Cys274 and other options for crosslinking.  A close up view of the 
amino acids and DNA bases surrounding Cys274 and the L1 loop is shown.  Cys274 and the 
cytosine bearing the linker are shown in red.  The L1 loop is rendered in beige with Lys117 
(Lys120 human numbering) colored in yellow.  The base Lys120 has been shown to contact in 
1TSR is also colored in yellow.  Thr281 and the phosphate group it contacts is colored in 
magenta.  Distances are shown as dashed orange lines and labeled. 
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Two different crosslinking strategies, both using the same DNA sequence that previously 
crystallized with the p53DBD tetramer, were attempted.  The first attempt had two backbone 
linkers per DNA strand (Figure 2.40).  DNA yields were preciously low, but some tetramer was 
able to be purified and a few crystallization conditions were tried.  One condition yielded 
crystals that were difficult to reproduce. 
The second type of crosslinking, referred to as mixed crosslinking, incorporated one base 
linker and one backbone linker (Figure 2.41).  The L1 loops of subunits B and D are present at 
the tetramerization interface, while subunits A and C have their L1 loops facing outwards (Figure 
2.28).  From this, we decided that only subunits B and D needed backbone crosslinking while 
subunits A and C could still have base crosslinking and not perturb the L1 loop at the 
tetramerization interface.  This type of DNA strand was easier to synthesize and lead to higher 
yields.  The p53DBD/DNA complex was purified and crystallization was attempted.  One 
condition yielded crystals after at least 1 month.  Unfortunately, these crystals did not diffract at 
the home source. 
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Figure 2.40: DNA bearing two backbone linkers.  This DNA corresponds to the first attempt to 
move the linker away from the L1 loop.  The phosphate group between the two magenta bases 
bears the cystamine linker.  This DNA duplex sequence is the same as the duplex used to 
crystallize the p53DBD/tetramer by base crosslinking. 
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Figure 2.41: DNA with mixed crosslinking.  This DNA corresponds to the second attempt to 
move the linker away from the L1 loop.  The phosphate group between the two magenta bases 
and the red cytosine bear a cystamine linker.  This DNA duplex is the same in sequence as the 
duplex used to crystallize the p53DBD/tetramer by base crosslinking. 
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2.4. New p53 Tetramers 
 
 
2.4.1. Self Assembled Tetramer (Chen et al, 2010) 
 
Since the publication of the tetramer reported in this text, a human tetrameric 
p53DBD/DNA structure has been reported(Chen et al, 2010).  This self-assembled complex was 
crystallized after an exhaustive search of many DNA consensus sequences with varying flanking 
bases of different lengths. 
Similar to 3EXJ and 3EXL, each subunit of this new tetramer forms the previously reported 
DNA and dimerization contacts in addition to having the same overall structure (Cα RMSD ≤ 
0.601 Å).  Each dimer-dimer interface (A-D, B-C) is also symmetrical and the B-form DNA has no 
discernable bend(Chen et al, 2010). 
While the many of the previously highlighted residues are involved in dimer-dimer contacts, 
they mediate different interactions.  Also well-ordered at the dimer-dimer interface are more 
p53DBD N terminal residues.  In 3EXJ, the first modeled residue is 98 while in 3KMD, it is 92.  
These 6 residues are present at the dimer-dimer interface and contribute to the increase in 
contacting surface area (665 Å2 vs 897 Å2)(Chen et al, 2010).  There is also a shift in the way the 
subunits are interacting at the dimer-dimer interface, which also leads to more extensive 
contact between the two subunits.   
The authors assert that the crosslinked tetramer could not form this conformation because 
of the tether(Chen et al, 2010).  However, this seems unlikely for several reasons.  Granted, the 
tether is longer than the distance between the sulfur of Cys274 and the N4 of the crosslinked 
cytosine so the extra atoms must be somewhere.  To the left, the H2 helix is packs close to the 
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DNA and to the right, the area has the flexible L1 loop followed by mostly open space.  It is 
extremely likely that the linker loops towards the right.  Because the new placement of the L1 
loop is an area where nothing exists in 3KMD (Figure 2.42), it also seems unlikely that its new 
placement is hindering any sort of tetramerization.   
It is possible that alternatively crosslinked tetramers will look much like 3KMD, 3EXJ or they 
could assemble with yet another unreported dimer-dimer interface.  These differences simply 
underscore the inherent plasticity in the DNA double helix and the p53DBD protein under 
conditions of tetramerization. 
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Figure 2.42: 3KMD vs. 3EXJ tetramerization.  Superposition of both tetramers via subunit A 
(right).  Subunits D (left), A (right), and DNA of 3KMD (purple, blue, dark blue) and 3EXJ (dark 
green, bright green, light green) are shown.  The shift of subunit D in 3KMD is easily seen 
compared to subunit D of 3EXJ.  The L1 loop and H2 helix of subunit D is labeled for both 
tetramers.  Cys274 is shown as a stick model to highlight the area of crosslinking for 3EXJ.  The 
dimer-dimer interface for both tetramer is also labeled. 
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2.5. p53 Tetramerization and Conclusions 
 
Considering the proposed variability of the dimer-dimer contacts within the tetrameric 
p53DBD bound to DNA, one might ask why p53 binds DNA as a tetramer.  This could simply 
be to increase the affinity of p53 for DNA.  It is also possible that other regions of p53 
interact with the DNA binding domain to support tetrameric binding to DNA.  Correlating 
with this possibility, the N- and C- terminal ends of the p53DBD are located at the dimer-
dimer interface (Figure 2.31, Figure 2.32, Figure 2.33).  Given that p53 has been reported to 
interact with many proteins, it is also possible that the p53DBD tetramer bound to DNA 
provides a unique protein contact surface.  Taken together, these correlations suggest that 
the p53DBD domain may play a more active role in p53 function than simply providing a 
scaffold for DNA binding.  
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2.6. Future Directions 
 
Tetramerization of p53 in the context of the full length protein is still a large research 
interest.  Where is the tetramerization domain once the core domains are bound properly to 
DNA?  Some small angle X-ray scattering(Tidow et al, 2007) as well as electron microscopy 
studies(Okorokov et al, 2006) have postulated where these domains reside, but it is still under 
investigation.  The L1 loop and the importance (or not) of Lys117/Lys120 is still under debate, as 
well. 
To that end, it would be useful to improve the crystals with mixed crosslinking and 
potentially collect a dataset.  Chen et al. report that their Lys120 makes a base specific contact 
when no tethers are used and Kitayner et al. show that the L1 loop is almost always in the same 
conformation regardless of DNA sequence used, but the sequence of 5’ – GAG –3’ has not been 
tested in their systems.  Given the low cancerous sensitivity of Lys120(Cho et al, 1994), it is still 
up in the air as to whether Lys117 needs to be in that conformation or it could move to the 
tetramerization interface when the DNA sequence is right. 
All of the structural work thus far has only focused on icosameric sequences.  El Deiry et 
al proved that p53 can bind to half sites that are separated by up to 13 base pairs(El-Diery et al, 
1992).  What do those tetramers bound to DNA look like?  Do the DBDs have any contact at all?  
Do the DBDs bend the DNA in such a way that protein-protein interactions can still occur?  It 
would be interesting to pursue some non-icosameric sequences for crystallization study and 
answer more of the questions that this fascinating protein poses. 
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CHAPTER 3 
Identification and characterization of small molecule human papillomavirus E6 inhibitors 
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3.1. Introduction 
 
3.1.1. Human papillomaviruses 
 
More than 130 different types of mucosal and cutaneous human papillomaviruses (HPVs) 
have been identified.  A phylogenetic tree of HPVs, which has been developed based on the 
nucleotide sequence of the major capside protein L1, breaks the family into five genera(de 
Villiers et al, 2004).  
 The beta genus is comprised of several HPV types that preferentially infect the skin and 
have circumstantially been linked to non-melanoma skin cancers.  The gamma, mu, and nu all 
contain HPV types that lead to the development of cutaneous papillomas and warts(de Villiers 
et al, 2004).   
Approximately 30 mucosal HPVs types fall within the alpha genus(de Villiers et al, 2004; 
Hausen, 2002).   This group can be further subdivided into low risk HPVs (e.g. types 6 and 11) 
and high risk HPVs (e.g. types 16 and 18) with the majority infecting the mucosa of the genital 
tract.  Low risk HPVs cause benign cellular proliferations leading to cutaneous or genital warts 
and papillomas.  High risk HPVs, on the other hand, are associated predominantly with 
carcinomas of the anogenital tract(Hausen, 1996; Hausen, 2002).  Cervical cancer is one the 
leading causes of women’s death in developing countries and is the sixth most common cancer 
in women worldwide(Baseman & Koutsky, 2005).   
Regardless of genus, all HPVs have a circular, double stranded DNA genome of 
approximately 8000 base pairs and containing 8 – 9 open reading frames(Ghittoni et al, 2010) 
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(Figure 3.1). Following infection at the basal layers of stratified epithelia, the early genes (E1, E2, 
E4, E5, E6, and E7) are turned on promote viral replication.  As the virus moves up the 
stratification, the late genes L1 (major capsid protein) and L2 (minor capsid protein) are 
expressed so new viruses can be packaged and shed upon cellular rupture (Figure 3.2) (Doorbar, 
2005; Ghittoni et al, 2010).  An area of noncoding DNA, termed the long control region (LCR), is 
also present between the L1 and E6 open reading frames.  It can vary in length between viral 
types and is involved in regulation of viral DNA replication/transcription(Ghittoni et al, 2010). 
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Figure 3.1: Genome of the human papillomavirus type 16.  The circular, double stranded DNA 
genome is denoted schematically.  The open reading frame for each gene is listed along with a 
designation for each gene product’s function.    This figure is adapted from (Ghittoni et al, 2010). 
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Figure 3.2: Infection of epithelia by HPVs.  The far left panel shows a cross section of stratified 
epithelia.  The stratification is created by cells at undergoing differentiation from basal cells 
(actively dividing, purple cells at the bottom of the cross section) to keratinocytes (terminally 
differentiated cells, top of the cross section).  The green cells represent those infected with HPV 
and are still actively dividing throughout the stratification.  The cluster of green cells near the 
top of the cross-section represents a lesion, which would be visible under the microscope.  The 
right hand side of the figure shows where in the stratification each gene of the HPV genome is 
being expressed.   This figure was adapted from (Doorbar, 2005). 
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3.1.2. E6 and E7 oncoproteins 
 
Most HPV infections are cleared with time due to the cellular immune response.  However, 
a small proportion of infections become chronic due to the integration of the high risk viral 
genome into the hosts’ chromosomes.  Expression of the viral oncoproteins E6 and E7 is 
typically increased once the viral genome has been integrated, which leads to cell proliferation 
by disruption of the cell cycle and eventual immortalization of infected cells, chromosomal 
instability and malignant transformation(Munger & Howley, 2002). 
Integration of the HPV genome happens randomly within the host genome, but it is 
suspected that it may happen more frequently at fragile chromosomal spots.  The frequency of 
integration can be correlated with the severity of cervical disease(Wentzensen et al, 2004).  
Following integration, most of the HPV genes are no longer expressed, except for the oncogenes 
E6 and E7.  Continual expression of these two genes is necessary to maintain malignancy while 
suppression of both genes results in cellular death(Alvarez-Salas & diPaolo, 2007).   
The major pathway of cell cycle disruption involves a concerted effort from both high risk E6 
and E7.  In healthy cells, the p110RB family of proteins (pRB) is bound by the family of 
transcription factors E2F/DP (E2F).  Phosphorylation of pRB results in the disruption of the 
pRB/E2F interaction and subsequent entrance of the cell in to the S phase(Dyson, 1998).  E7 is 
small, dimeric protein(Liu et al, 2006) that can bind to pRB and mimic the phosphorylation 
signal(Munger & al, 2001), which cause premature release of E2F and brings about the 
degradation of pRB (Figure 3.3).  In response to this deregulated entrance into the S phase, the 
tumor suppressor protein p53 would be activated causing the cell to either undergo cell cycle 
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arrest or apoptosis.  In an HPV positive cell, however, E6 binds to the cellular E3 ligase, E6-
Associating Protein (E6AP), and this heterodimer then targets p53 for degradation via the 
ubiquitin-proteasome pathway(Huibregste et al, 1993; Scheffner, 1998; Scheffner et al, 1993) 
(Figure 3.3). 
 Both E6 and E7 have been shown to have other functions outside of this pathway.  E7 
can associate with p21WAF1/CIP1 and p27KIP1 to disrupt the cell cycle, in addition to interacting with 
the cyclin A/CDK2 complex and altering kinase activity within the cell(Arroyo et al, 1993; He et 
al, 2003).    On the other hand, E6 has been implicated in a wide range of other activities.  The C 
terminus of E6 contains a PDZ binding motif that targets cytoplasmic membrane proteins, 
including hDLG, Scribble, MUPP1, and MAG1-3(Gardiol et al, 1999).  E6 can bring about 
degradation of these proteins, which causes the loss of large protein scaffolds, cell-to-cell 
contacts, and cell polarity(Gardiol et al, 1999).  Also, the C terminus of E6 can bind four-way 
DNA holliday junctions(Ristriani et al, 2000; Ristriani et al, 2001) suggesting other ways that it 
can lead to cellular transformation.  Finally, E6 has been implicated in disrupting p53-dependant 
gene activation by inhibiting p300/CBP acetylation(Patel et al, 1999; Thomas & Chaing, 2005). 
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Figure 3.3: The concerted effort of E6 and E7 to cause cell cycle disruption.  E7 binds pRB, 
forces the cell into the S phase and brings about pRB degradation.  In a cell absent of E6, p53 
levels would rise and transcribe genes involves in cell cycle arrest or apoptosis.  In an HPV 
positive cell, E6 has bound E6AP and together they target p53 for degradation via the ubiquitin-
proteosome pathway. 
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3.1.3. Structural studies of E6 
 
The structure of E6 has been sought since its discovery in 1987(Seedorf et al, 1987).  
Unfortunately, this 158 amino acid protein has been difficult to study due to its propensity for 
aggregation and precipitation (Lipari et al, 2001; Nomine et al, 2003; Nomine et al, 2006).   
E6 is known to be comprised of both an N and C terminal domain, one of which most likely 
arose from a gene duplication event.  Sequence similarity between the two domains is low (< 
20%), however quirks are seen in the sequence.  For example, the amino acid motif of Cys-X-X-
Cys is found four times within the entire protein with the sequence XXXLXXXE following both the 
first and third Cys-X-X-Cys motif(Cole & Danos, 1987).  The chances of these quirks arising from a 
situation other than gene duplication are remote. 
Schematically, the structure of full length E6 is shown in Figure 3.4.  Briefly, the N terminal 
domain is connected to the C terminal domain by a central, conserved linker.  The extreme ends 
of the protein each have a loop region, with the C terminal loop containing a PDZ binding motif.  
Both domains each contain two Cys-X-X-Cys motifs, where all four cysteines ligate one Zn2+ 
ion(Nomine et al, 2005). 
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Figure 3.4: Schematic representation of the full length HPV16 E6 protein.  Residues numbers 
are given for each individual domain and the amino acids involved in Zn2+ ligation.  This figure is 
adapted from (Nomine et al, 2005). 
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In 2001, Cordingley and colleagues studied the biochemical properties of the HPV16 E6 N 
terminal domain.  Their construct contained residues 2 – 77 and was called E6-N.  They assert 
that E6-N was highly soluble in low salt buffers.  After an array of studies, they determined that 
one Zn2+ ion was bound by the domain, the exact cysteines required for Zn2+ ligation, and 
postulated that it was the C terminal domain of E6 that was responsible for the full length 
protein’s purification difficulties(Lipari et al, 2001). 
Two years later, work by the laboratory of Gilles Travé challenged Lipari et al’s results by 
showing that it was the C terminal domain of HPV16 E6 that was well behaved.  They expressed 
individual constructs of each domain (residues 7 – 83 and residues 87 – 158) and found that the 
N terminal domain was poorly behaved while the C terminal domain was easily expressed and 
concentrated up to 1 mM(Nomine et al, 2003).  These results were also supported by work 
performed in our laboratory.  The authors were then able to show that the domain was 
monomeric and had equal proportions of α helix and ß sheet.  Interestingly, this domain also 
retained the full length protein’s ability to bind four-way DNA Holliday junctions(Nomine et al, 
2003). 
The full length HPV16 E6 protein contains 14 cysteine residues.  Only 8 are required for zinc 
ligation and the remaining 6 are not conserved.  Nominé et al. used this information to their 
advantage and mutated the nonconserved cysteines to serines (known as E6 6C/6S) in hopes of 
minimizing the aggregation and precipitation problems of wild type E6(Nomine et al, 2003).  
They further showed that E6 6C/6S behaved indistinguishably from wild type E6 in both in vitro 
and in vivo p53 degradation assays(Nomine et al, 2003; Nomine et al, 2006).   
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Travé and colleagues followed up their biochemical study with a nuclear magnetic 
resonance (NMR) structure of the C terminal domain(Nomine et al, 2006) (Figure 3.5).  In 
support of the previous work, it was found to adopt a novel α/ß fold and ligate one Zn2+ ion.  The 
structure, which is shown in Figure 3.5, has a three stranded anti-parallel ß sheet with two of 
the three short α helices packing on one side.  Zn2+ ligation occurred via cysteines from H3 and 
the L2 loop.  The domain has a main hydrophobic core that centers around Trp132, but also has 
a large hydrophobic patch including residues Tyr81, Tyr92, Leu99, and Asn127 that is solvent 
exposed(Nomine et al, 2006). 
Given that these domains are probably related by a gene duplication event and were 
predicted to have similar secondary structure, Nominé et al modeled what the N terminal 
domain could look like by adding its residues to the Cα backbone of the C terminal domain.  
Interestingly, several conserved hydrophobic residues were found to create a patch on one side 
of the N terminal model, leading the researchers to believe that these patches could be where 
the two domains contact each other(Nomine et al, 2006). 
After exploring several possibilities for assembly, the final model minimized steric clashes, 
optimally fit secondary structure, and buried most of the hydrophobic patches.  The full length 
model has a central six stranded anti-parallel ß sheet with each Zn2+ ion at opposite ends of the 
protein(Nomine et al, 2006) (Figure 3.6).   
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Figure 3.5: NMR structure of HPV16 C terminal domain.  The C terminal domain of HPV16 E6 is 
shown in cartoon representation.  The three anti-parallel ß sheets are labeled, as well as the 
three α helices and two loops.  The Zn2+ ion is shown as an orange sphere.  This figure is adapted 
from (Nomine et al, 2006). 
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Figure 3.6: Full length model of HPV16 E6.  The C terminal domain NMR structure is shown in 
orange and the N terminal domain model is shown in blue. All secondary structure in the 
modeled N terminal domain is labeled the same as the C terminal domain.   The residues of 
missing N terminal, C terminal and linker regions are also listed with conserved residues colored 
in red.  The top panel is a 90° rotation out of the page of the bottom panel.  This figure was 
adapted from (Nomine et al, 2006). 
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Nominé et al’s model accurately explains the reasons for several highly conserved residues 
within E6’s sequence and even highlights some surface residues that could be necessary for 
E6AP recruitment(Nomine et al, 2006).  Unfortunately, the model is an educated guess and lacks 
the loops of the protein, particularly the conserved linker region.  The authors did attempt an 
NMR structure of the full length protein, but once the N terminal domain was added to the 
construct, it failed to behave well enough for NMR studies.   Since a model cannot be probed in 
the same ways as a full length NMR or crystal structure could be, the hunt continues. 
 
3.1.4. Previous studies to inhibit E6 function 
E6AP is an E3 cellular ligase that is expressed ubiquitously in human cells.  The full length 
protein is 875 amino acids, with the final 357 amino acids comprising the homologous to E6AP C 
terminus or HECT domain, which catalyzes the transfer of ubiquitin to target proteins.  When E6 
is not present, E6AP has no interaction or shows any propensity for targeting p53 for 
degradation(Be et al, 2001; Elston et al, 1998; Huang et al, 1999). 
A short, α helical peptide N terminal to the HECT domain (residues 403 – 421) is necessary 
and sufficient for E6 binding.  A few other peptides have also been shown to bind E6 so a broad 
consensus sequence has been established: L h x φ L s h, where L is leucine, h is an amino acid 
that can accept a hydrogen bond, x is any amino acid, φ is a hydrophobic residue, and s is a 
small amino acid like glycine or alanine(Be et al, 2001).   
When E6 is bound to E6AP, the complex binds p53’s core domain for the transfer of 
ubiquitins(Cooper et al, 2003; Huibregste et al, 1993; Li & Coffino, 1996).  Because the binding of 
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E6 to E6AP is a prerequisite to p53 degradation, many laboratories have focused on ways to 
block E6 binding to E6AP, which would subsequently block p53 degradation and bring about a 
return of p53 tumor suppressor function. 
Early studies worked with RNAi(Niu et al, 2006) and anti-sense oligodeoxynucleotides 
(Marquez-Gutierrez et al, 2007b), which directly affected E6 levels within cell and animal 
models.  Both showed an increase in apoptosis or a limit in tumor growth after introduction of 
the oligonucleotides(Marquez-Gutierrez et al, 2007a; Niu et al, 2006).  Specific protein inhibitors 
were also developed, including intrabodies(Griffin et al, 2006) and alpha helical peptides(Butz et 
al, 2000; Liu et al, 2004), which were also able to show modest activity.    Finally, ten small 
molecules inhibitors were identified by Baleja et al. after pharmacophore development and in 
silico screening(Baleja et al, 2006), but only one compound proved to be active in cells at high 
concentrations. 
Historically, small molecules were developed to target enzymes, many of which already had 
small molecule substrates that could be mimicked(Arkin & Wells, 2004).  Protein-protein 
interactions face many more challenges as drug targets due to the relative flatness and size of 
the interfaces, flexibility of the proteins upon binding, and stiochiometry of binding(Arkin & 
Wells, 2004).  However, certain protein-protein interfaces seem to be amenable to small 
molecules, particularly those with small “hot spots” or involving binding to small peptides.  The 
recent development of potent competitive antagonists towards the binding of BCL-XL to a 16 
residue α helix of BAK(Degeterev, 2001; Kutzki, 2002) shows that small molecules can be 
developed to disrupt protein-protein interactions.  Similar to those proteins, E6 is a small, 
monomeric protein of 19 kDa(Lipari et al, 2001; Nomine et al, 2003) and the region of E6AP 
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necessary and sufficient for E6 binding is a 20 amino acid α helix(Be et al, 2001; Cooper et al, 
2003; Huibregste et al, 1993), making this protein-protein interaction a feasible target for 
inhibitor development.(Arkin & Wells, 2004) 
With the recent release of the vaccines Guardasil (Merck) and Cervarix (GlaxoSmithKline), 
many feel that searching for more drug candidates to fight HPV infection is a moot point.  
However, the vaccine cost is still high and out of reach for some people in the United States, not 
to mention countries with less developed healthcare systems where rates of cervical cancer are 
still quite high.  Also, vaccines offer little help to those already infected with HPV and showing 
signs of cervical intraepithelial neoplasia (CIN) or cancer.  Considering that previous studies 
correlated cell cycle arrest and apoptosis with decreased of E6 activity, a small molecule 
inhibitor of E6 function could be a useful therapeutic tool and a crystal structure of E6 would a 
valuable asset to the field. 
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3.2. Materials and Methods 
 
 
3.2.1. Growth and purification of E6M-GST, MBP-E6AP, and E6M 
 
E6M-GST: Residues 1 – 158 of HPV16 E6 fused C terminally to glutathione-S-transferase were 
cloned into the pET28a vector (Invitrogen).  Using the same idea as Nomine et al(Nomine et al, 
2006), the nonconserved cysteine residues were mutated to the analogous residue in HPV 1A 
E6.  DE3 Escherichia coli (E. coli) cells were transformed with the plasmid, grown in the presence 
of 50 µg/mL kanamycin, and induced with 1 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG) 
and 75 µM Zn(OAc)2 overnight at 18°C.  Cell pellets were resuspended in 20 mM Hepes, pH 7.5, 
500 mM NaCl, 10 mM ß-mercaptoethanol (BME), 1 uM Zn(OAc)2, and 10 µg/mL 
phenylmethanesulfonyl fluoride (PMSF).    Cells were lysed by sonication at 4°C and the 
insoluble fraction was separated by centrifugation at 18,000 rpm (SS-34, Sorvall) for 30 minutes.  
The soluble fraction was passed over pre-equilibrated glutathione resin (GE Healthcare), washed 
and protein was eluted with buffer containing 10 mM reduced glutathione (Sigma).  Protein was 
aliquoted immediately and frozen on dry ice followed by long term storage at -80°C. 
 
MBP-E6AP: Residues 363 to 440 of E6AP (isoform II) were cloned into the pMAL vector (NEB).  
DE3 E. coli cells were transformed with the plasmid, grown in the presence of 100 µg/mL 
ampicillin, and induced with 1 mM IPTG overnight at 18°C.  Cell pellets were resuspended in 20 
mM Hepes, pH 7.5, 200 mM NaCl, 10 mM BME, and 10 µg/mL PMSF.  Cells were lysed by 
sonication at 4°C and the insoluble fraction was separated by centrifugation at 18,000 rpm (SS-
34, Sorvall) for 30 minutes.  The soluble fraction was passed over pre-equilibrated amylose resin 
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(NEB), washed, and protein was eluted with buffer containing 10 mM maltose (Fisher).  Protein 
was concentrated to ~ 300 µM, aliquoted and frozen on dry ice followed by long term storage at 
-80°C.  A similar construct of residues 403 – 421 (isoform II) were cloned into the pMAL vector 
and purified in the exact same manner. 
 
GST-E6AP: Residues 403 – 421 (isoform II) were cloned into the pGEX vector (GE Healthcare).  
DE3 E. coli cells were transformed with the plasmid, grown in the presence of 100 µg/mL 
ampicillin, and induced with 1 mM IPTG overnight at 18°C.  Cell pellets were resuspended in 20 
mM Hepes, pH 7.5, 100 mM NaCl, 10 mM BME and 10 µg/mL PMSF.  Cells were lysed by 
sonication at 4°C and the insoluble fraction was separated by centrifugation at 18,000 rpm (SS-
34, Sorvall) for 30 minutes.  The soluble fraction was passed over pre-equilibrated glutathione 
resin (GE Healthcare), washed and protein was eluted with buffer containing 10 mM reduced 
glutathione (Sigma).  Protein was concentrated to ~ 15 mg/mL, aliquoted and frozen on dry ice 
followed by long term storage at - 80°C.  
 
E6M: Residues 1 to 158 of HPV16 E6 was cloned into the pET-DUET vector multiple cloning site 
(MCS) 1.  Using the same idea as Nomine et al, the nonconserved cysteine residues were 
mutated to the analogous residue in HPV 1A E6.   The full length UBE3, the yeast small ubiqutin-
like modifier (SUMO) protein and Smt3 cleavage site had already been inserted into this vector 
after the 6x His tag but before the multiple cloning site.  DE3 or 520 E. coli cells were 
transformed with the plasmid, grown in the presence of 100 µ/mL ampicillin, and induced with 1 
mM IPTG and 75 µM Zn(OAc)2 overnight at 18°C.  Cell pellets were resuspended in in 20 mM 
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Hepes, pH 7.5, 500 mM NaCl, 10 mM BME, 1 uM Zn(OAc)2, 5 mM imidazole, and 10 µg/mL 
PMSF.  Cells were lysed by sonication at 4°C and the insoluble fraction was separated by 
centrifugation at 18,000 rpm (SS-34, Sorvall) for 30 minutes.  The soluble fraction was passed 
over pre-equilibrated Ni-NTA resin (Qiagen), washed with buffer plus 30 mM imidazole and the 
protein was eluted on an imidazole gradient of 30 mM to 500 mM.  Cleanest fractions were 
pooled and dialyzed overnight at 4°C into 20 mM Hepes, pH 7.5, 500 mM NaCl, and 10 mM BME.  
Protein was recovered and 500 µg of previously purified Smt3 was added per 50 mL of purified 
SUMO-E6M.  The cleavage reaction was incubated for 1 hour on ice, then passed over pre-
equilibrated Ni-NTA resin (Qiagen).  Purified E6M was washed off the Ni-NTA resin with 20 mM 
Hepes, pH 7.5, 500 mM NaCl, 10 mM BME, and 20 mM imidazole.  Protein was either used 
within 12 hours or aliquoted and frozen on dry ice followed by long term storage at -80°C. 
 
3.2.2. Pulldown of E6M and MBP-E6AP 
 
50 µL of resin was pre-equilibrated with 20 mM Hepes, pH 7.5, 500 mM NaCl, 10 mM BME.  
30 µg of matching tagged protein was added with an equimolar amount of the partner protein, 
excess buffer, and incubated at 4°C for one hour on the nutator.  Resin was washed with buffer 
and then ran out on an SDS-PAGE gel to determine extent of binding between the proteins.  
Negative controls were performed with tag alone plus the partner protein. 
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3.2.3. E6M complex purification and crystallization 
E6M was purified as described above in large volume (~ 15 mL per 3 L E. coli growth) at ~ 0.2 
mg/mL.  An equimolar concentration of previously purified MBP-E6AP or DSHS00884 was added 
to the dilute E6M protein.  The mixture was allowed to sit on ice for one hour then concentrated 
with a 10,000 MWCO filter (Amicon).  For E6M + MBP-E6AP, the complex was then further 
purified on Superdex 200a column (GE Healthcare) and concentrated to 15 mg/mL as 
determined by UV-absorbance at 280 nm.  Crystals were grown in 1.5 M NaCl and 10% v/v 
ethanol.  E6M + DSHS 00884 was concentrated to 1.8 mg/mL, as determined by a Bradford 
Assay.  Crystals were grown in several conditions: 1. 200 mM potassium tartrate tetrahydrate, 
20% PEG 3350, 2. 200 mM sodium malonate, pH 7.0, 20% PEG 3350, 3. 200 mM ammonium 
citrate tribasic, pH 7.0, 20% PEG 3350, and 4. 200 mM citrate tribasi dehydrate, 20% PEG 3350. 
 
3.2.4. Enzyme-linked immunosorbance assay (ELISA) 
 
50 µL of 30 nM E6M-GST (20 mM Hepes, pH 7.5, 500 mM NaCl, 10 mM BME) was added to 
each well in a 384-well, black, glutathione coated plate (NUNC).  After one hour of incubation 
with shaking, all wells were washed with 20 mM Hepes, pH 7.5, 500 mM NaCl, 10 mM BME, and 
0.1% TWEEN-20.  50 µL of 6 µM MBP-E6AP (1x PBS, 10 mM DTT, 0.1% TWEEN-20, buffer will be 
used for the rest of the assay) was then added to each well followed by 0.5 µL of 
DMSO/compound.  After one hour of incubation with shaking, all wells were washed with 
buffer.  50 uL of 1:15,000 anti-MBP-HRP (NEB) was then added to each well and plates were 
shaken for one hour.  Wells were washed one final time with buffer and 50 uL of ELISA Pico 
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chemiluminescence substrate (Pierce) was added and wells were read with a plate reader 
(Wallac) after thirty minutes.  Either 30 nM GST or 6 µM MBP were used for negative controls. 
 
3.2.5. High throughput assay screening / data processing 
 
Three different diverse chemical libraries were screened: Spectrum (Microsource; 2000 
compounds), HitFinder (Maybridge; 14,000 compounds), and Orthogonally Pooled Screening 
libraries (OPS, Lankenau Institute for Medical Research; 60,000 compounds), resulting in nearly 
80,000 total compounds screened.  The Spectrum library was screened with a single compound 
per well in duplicate, while the Maybridge and OPS libraries were screened in a compressed 
format of 5 compounds per well based on the Devlin et al. published method for screening and 
deconvolution of data(Devlin et al, 1996).  Spectrum and HitFinder compounds were tested at 
final concentrations 10 µM and the OPS library was screened at final concentrations of 6 – 10 
µM. 
Each 384 well plate receiving compounds during screening was set up to have positive 
controls (E6-GST + MBP-E6AP + DMSO) in columns 2 and 23 and negative controls (GST + MBP-
E6AP + DMSO) in columns 1 and 24 and compounds in columns 3 – 22.  Uniformity plates (192 
positive controls, 192 negative controls) were placed throughout the screening plates to ensure 
both assay and results reliability.   
Percent E6-E6AP binding was calculated from raw luminescent values for each test 
compound (% inhibition = [average positive signal – test compound signal] / [average positive 
signal – average minimum signal] * 100%).  For the all screens, compounds that displayed three 
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standard deviation units (~ 50% inhibition) from the average of E6-E6AP binding in the presence 
of DMSO was classified as active.  Software applications developed by CeuticalSoft (OpenHTS) 
were used to deconvoluate the orthogonally compressed data for both HitFinder and OPS.  The 
data was grouped into four categories: actives (compounds that displayed > 50% inhibition of 
E6-E6AP binding and cleaning mapped to a unique well in both the horizontal and vertical 
direction), ambiguous (compounds that mapped to two or more wells in either dimension), 
orphan (compound displayed inhibition in one direction but not the other) and inactive 
compounds.  
 
3.2.6. Fluorescent thermal stability assay 
Individual 20 uL reactions were set up with 4 uM E6M, 1:1000 SYPRO orange (Invitrogen), 10 
µM compound (final DMSO concentration of 1%) and buffer with a final concentration of 20 mM 
Hepes, pH 7.5, 500 mM NaCl, and 10 mM BME.  Thermal melt curves were obtained by heating 
the protein from 20˚C to 80˚C and monitoring fluorescence at 580 nM using a 7900HT Fast Real 
Time PCR System (Applied Biosystems).  Because some compounds were autofluorescent, 
negative control reactions of each compound alone were also performed to show that their 
fluorescent properties did not change over the temperature range of the experiment and ensure 
that fluorescence was directly representing E6M melting only (data not shown).   
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3.2.7. In vitro p53 degradation assay 
 
In vitro translation: Full length, wild-type human p53 was cloned into the pRSETa vector 
(Invitrogen).  Full length, wild type human papillomavirus type 16 E6 was cloned into the pET28a 
vector (EMD Biosciences).  Using the TNT T7 coupled rabbit reticulocyte lysate systems 
(Promega), each protein was translated in separate reactions. 
 
Degradation:  Individual 10 µL degradation reactions were set up with 2 µL p53 translation 
reaction, 5 µL E6 translation reaction, 0.1 µL compound, and 2.9 µL buffer in a final 
concentration of 20 mM Tris, pH 7.5, 100 mM NaCl, and 2 mM DTT.  Positive control reactions 
included 0.1 µL DMSO; negative control reactions included 0.1 µL DMSO and 5 µL of a blank 
translation reaction instead of the E6 translation reaction.  All reactions were incubated at 30˚C 
for 2.5 hours.  Reaction were then mixed with SDS loading dye and heated at 90˚C for five 
minutes. 
 
Western Blotting: 3 µL of each reaction was run out on a 15% SDS-PAGE gel, transferred to PVDF 
membrane and then probed with anti-p53 (1:5000, Bp53-12, Santa Cruz Biotechnology) 
followed by anti-mouse conjugated to HRP (1:5000, Bio-RAD).  Bands were visualized by 
chemiluminesence (Pierce) and exposure to film (Kodak). 
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3.2.8. Cell maintenance 
 
C33A, SiHa, and HeLa cells were grown in 1x minimal eagle’s media (MEM, Cellgro) 
supplemented with 10% fetal bovine serum (Hyclone), 10 µg/mL penicillin-streptomycin 
(Cellgro), 2 mM ι-glutamine (cellgro), 1 mM sodium pyruvate (Cellgro), and 100 µM non-
essential amino acids (Gibco).  All experiments were carried out with cells passaged 30 times or 
less.  C33A and SiHa cell lines were ordered from ATCC, while the HeLa cell line was a gift from 
laboratory of Susan Janicki, Ph.D. 
 
3.2.9. Cell assays: toxicity, p53 levels, APO-one 
 
Toxicity Assay: 40 µL of 500 cells/µL C33A cells or 50 cells/µL SiHa/HeLa cells (harvested in 
media containing 20% FBS) were plated on Day 1 in each well of a 384 well, clear, tissue culture 
plate (NUNC).  On Day 2, 40 µL of DMSO/compound in media containing no FBS was added to 
each well and cells were incubated for 48 hours.  On Day 4, 8 µL of MTS reagent (Promega) was 
added to each well and the absorbance at 490 nm was read (Wallac) after 5 hours. 
 
p53 Levels: On Day 1, in a 6 well, clear, tissue culture plate, 400,000 SiHa or HeLa cells were 
plated with 2 mL of media.  On Day 2, 5 µL of DMSO/compound was added to 500 µL media, 
mixed, and all 500 µL were added to each well.  Cells were incubated for 48 hours and on Day 4, 
cells were washed with 2 mL of cold, sterile 1x PBS, then harvested with 600 µL of RIPA buffer 
with complete protease inhibitor cocktail (Roche).  Protein sample concentrations were 
normalized with the bicinchoninic acid (BCA) protein assay (Pierce).  28 µL of each sample was 
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run on a 12% SDS-page gel and transferred to a PVDF membrane.  All membranes were probed 
with three primary antibodies: p53 (1:1000 anti-p53 (Santa Cruz Biotechnologies)), cleaved PARP 
(1:1000 anti-cleaved PARP (Abcam)), and beta actin (1:5000 anti-beta actin (Abcam)).  All bands 
were visualized by chemiluminescence (Pierce) and exposure to film (Kodak).     
 
APO-One: 25 µL of 80 cells/µL SiHa/HeLa cells were plated on Day 1 in each well of a 384 well, 
clear, tissue culture plate (NUNC).  On Day 2, 0.5 µL of DMSO/compound was added to each well 
and cells were incubated for 48 hours.  On Day 4, 25 µL of APO-one reagent (Promega) was 
added to each well and, following excitation at 485 nm, the fluorescence at 521 nm was read 
(Wallac) after incubation at room temperature for 8 hours. 
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3.3. High Throughput Screening Results and Discussion 
 
3.3.1. Development of High Throughput Screen and Inhibitor Identification 
High throughput screening (HTS) for small molecule inhibitors of the E6 / E6AP interaction 
was designed around a modified sandwich enzyme-linked immunosorbance assay (ELISA).  Full 
length HPV16 E6 was fused C terminally to glutathione-S-transferase (GST).  MBP-E6AP (residues 
363 – 440, isoform II) was added to the wells at a concentration of 6 µM (the reported Kd of the 
protein-protein interaction(Zanier et al, 2005)), in the presence of a small molecule dissolved in 
DMSO or a DMSO control.  The extent of binding between the two proteins was assessed by 
incubation with the anti-MBP-HRP antibody (New England BioLabs) and chemiluminescence 
(Pierce) (Figure 3.7). 
The robustness of the assay was assessed using the Z factor parameter(Zhang et al, 1999).  
Using a 96 well format, we optimized conditions to obtain a Z factor of 0.784 (E6M-GST/GST + 
MBP-E6AP) and 0.624 (E6M-GST + MBP-E6AP/MBP).  Miniaturization to a 384 well format and 
automation optimization resulted in Z factors consistently above 0.60 (Figure 3.8).  
Three different diverse chemical libraries were screened: Spectrum (Microsource; 2000 
compounds), HitFinder (Maybridge; 14,000 compounds), and Orthogonally Pooled Screening 
libraries (OPS, Lankenau Institute for Medical Research; 60,000 compounds), resulting in nearly 
80,000 total compounds.  The Spectrum library was screened with a single compound per well in 
duplicate, while the Maybridge and OPS libraries were screened in a compressed format of 5 
compounds per well based on the Davlin et al. published method for screening and 
deconvolution of data(Devlin et al, 1996).  The initial screening resulted in 201 potential 
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inhibitors of the E6 / E6AP interaction that were further cherry picked for follow-up studies.  
This included orphan and ambiguous hits that came out of the use of compressed libraries.   
All potential hits, including orphans and ambiguous compounds, were cherry picked and 
retested at the screening concentration in the ELISA assay.  Following retesting, the number of 
potential inhibitors dropped to 54, producing a hit rate from the screen of 0.070% (Table 3.1). 
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Figure 3.7: Scheme for the high throughput screening assay.  The ELISA assay is represented 
here schematically.  DMSO or compound dissolved in DMSO was added with the MBP-E6AP. 
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Figure 3.8: Z factor graph.  A representative Z factor graph is shown for a 384 well plate: 192 
positive control (E6M-GST + MBP-E6AP6) wells, 192 negative control (GST + MBP-E6AP6) wells.  
The Z factor was calculated according to Zhang et al, 1999. 
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Library Name Library Size Hits Confirmed 
Cherry Picks 
Confirmed 
Compounds 
Spectrum 2000 compounds 7 4 4 
Maybridge 
HitFinder 
14,400 
compounds 
56* 13 12 
OPS 60,000 
compounds 
138* 37 14 
TOTALS 76,400 
compounds 
201 54 30 
 
Table 3.1: Screening summary.  Names of the libraries screened, their size, and the number of 
hits from each screen are listed.  Hits: Number of potential inhibitor compounds from initial 
screening.  Asterisks show which libraries included ambiguous and orphan hits to the original hit 
number.  Confirmed cherry picks: Number of potential inhibitors that again showed inhibition in 
the ELISA assay at the screening concentration.  Confirmed compounds: Compounds that, 
following purchase of powders, passed all secondary assays for inhibition. 
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3.3.2. Characterization of HPV-E6 Inhibitors in vitro 
We ranked the potency of the inhibitors by determining the inhibitor concentration that 
reduced the extent of binding between E6M-GST and MBP-E6AP by 50% (IC50 value).  For each of 
the inhibitors tested, fresh powders were ordered directly from commercial suppliers and 42 of 
the 54 compounds had IC50 values of 30 µM or less, with more than half of the inhibitors having 
IC50 values in the low to mid-nanomolar.  Table 3.2 reviews the IC50s and structures for the fully 
confirmed 30 inhibitors. 
To assay if compounds were nonspecifically inhibiting binding between E6M-GST and MBP-
E6AP by precipitating E6M-GST, a fluorescent thermal stability assay was employed.  This assay 
monitors protein unfolding in the presence of a given inhibitor where inhibitor binding is 
generally correlated with a change in the protein melting temperature curve.    Full length, 
untagged E6M was incubated at increasing temperature (20°C - 80°C) with either DMSO control 
or with compound.  The reporter dye, SYPRO orange (Invitrogen), which binds to hydrophobic 
regions of proteins that are generally exposed upon protein unfolding, was also added. 
The control reaction with DMSO showed that E6M was unstable from 20°C to approximately 
37°C, after which the protein melted in a standard sigmoidal fashion (Figure 3.9, Table 3.2).  
Overall, three different types of curves resulted from this assay with added compound.  
Fourteen compounds resulted in E6M melting curves that were indistinguishable from the 
protein melting curves without added compound. (Figure 3.9, Table 3.2).  Unchanged melting 
curves could indicate that compounds were binding E6M but not significantly stabilizing its 
structure or that the compound mediated its function in other ways, most likely by binding 
E6AP.  Twenty three compounds showed significant stabilization of E6M in the region of 20°C to 
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37°C, which suggested that these compounds were binding E6M (Figure 3.9, Table 3.2).  Finally, 
E6M in the presence of five compounds had an essentially constant fluorescence reading over 
the temperature range.  The flattened fluorescence curve was concluded to mean that the 
compound caused E6M to precipitate out of solution (Figure 3.9, Table 3.2).  This conclusion was 
supported by a simple in vitro test of mixing purified E6M with an equimolar concentration of all 
five compounds individually.  A white precipitate formed each time, which was pelleted by 
centrifugation and shown to be E6M by SDS-PAGE (data not shown).  These five compounds 
were eliminated from the pool of potential inhibitors. 
To establish if the E6 inhibitors could function to inhibit the ability of E6 to mediate p53 
degradation, we assayed the remaining 37 compounds that did not appear to cause E6M 
precipitation in a p53 degradation assay.  We first used a cell free system to factor out the ability 
of compounds to enter cells.  We anticipated that this assay would also help eliminate 
compounds that were false positives in the ELISA assay, such as those compounds that inhibited 
GST/glutathione binding or HRP function, and possibilities that could not be easily tested the 
fluorescence assay, such as MBP or E6AP precipitation.  To carry out these studies, full length, 
wild type HPV16 E6 and full length, wild type human p53 were translated in separate reactions 
using the TNT T7 Coupling Reticulocyte System (Promega).  Equal amounts of each reaction 
were mixed together with compound and excess lysate, which contains E6AP and the machinery 
for ubiquitin-mediated degradation.  The amount of p53 present in each sample was 
determined by a Western blot against the N terminus of human p53 (Santa Cruz Biotechnology).  
These studies revealed that 7 compounds showed no effect on p53 degradation in the cell 
free system.  Of the 30 compounds that did modulate p53 degradation, approximate IC50s 
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ranged from nanomolar to high micromolar (Table 3.2, Figure 3.10) with the IC50 value 
representing the concentration of compound needed to bring degradation of p53 down 50%.  
Together, these studies show that we have identified 30 HPV-E6 inhibitors that are able to block 
the ability of E6 to mediate its oncogenic property of p53 degradation in a cell free system. 
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Figure 3.9: Effect of inhibitors on E6 thermal stability.  Replicate data (blue and red) for 
fluorescence at 580 nm vs temperature for each compound is graphed.  (A) E6M in 20 mM 
Hepes, pH 7.5, 500 mM Nacl, and 10 mM BME and 1% DMSO.  Inherent protein instability is 
seen in the region of 20°C to 37°C.  (B) E6M with CD11403, representing a compound that does 
not significantly stabilize E6M and results in a curve with a similar shape as E6M with DMSO 
alone.  (C) E6M with gossypetin, representing the best compound to stabilizes E6M.  The results 
show a curve that no longer has the region of instability from 20°C to 37°C.  (D) E6M with 
inhibitor Compound 9, a previously identified inhibitor from Baleja et al(Baleja et al, 2006), 
which results in E6M precipitation and the flattened curve. 
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Figure 3.10: p53 degradation assay results.  Westerns of p53 degradation reactions treated with 
increasing concentrations of compound.  Positive controls were E6 + p53 + DMSO while negative 
controls were p53 + blank reaction + DMSO. 
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Name ELISA IC50 p53 Degradation 
~IC50 
Thermal 
Stability 
Structure 
 
C14 
 
30.6 ± 4.7 nM 
 
10 μM 
 
Stabilized 
 
 
C17 
 
86.1 ± 37.3nM 
 
10 – 100 µM 
 
Unchanged 
 
 
Purpurin 
 
143 ± 78 nM 
 
250 nM 
 
Stabilized* 
 
 
E17 
 
148 ± 42 nM 
 
10 – 100 nM 
 
Stabilized 
 
 
Gossypetin 
 
170 ± 21 nM 
 
250 nM 
 
Stabilized 
 
 
B15 
 
178 ± 122 nM 
 
10 – 100 µM 
 
Unchanged 
 
 
Baicalein 
 
235 ± 74 nM 
 
250 nM 
 
Stabilized* 
 
 
A19 
 
295 ± 38 nM 
 
10 – 100 µM 
 
Stabilized 
 
 
S05659 
 
311 ± 1.6 nM 
 
250 nM – 2.5 µM 
 
Unchanged 
 
 
D5 
 
347 ± 218 nM 
 
10 μM 
 
Stabilized 
 
 
C6 
 
363 ± 24 nM 
 
1 – 10 µM 
 
Unchanged 
 
 
A14 
 
457 ± 14 nM 
 
100 μM 
 
Unchanged 
 
 
A22 
 
477 ± 166 nM 
 
1 – 10 µM 
 
Stabilized* 
 
 
C9 
 
496 ± 49 nM 
 
10 – 100 µM 
 
Stabilized 
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DP00966 
 
573 ± 323 nM 
 
250 µM 
 
Unchanged 
 
 
JFD00458 
 
703 ± 54 nM 
 
250 nM 
 
Stabilized* 
 
 
B11 
 
749 ± 310 nM 
 
2.5 µM 
 
Unchanged 
 
 
RH02007 
 
1.41 ± 0.05 μM 
 
2.5 – 25 µM 
 
Stabilized* 
 
 
C22 
 
1.79 ± 0.24 µM 
 
100 μM 
 
Stabilized 
 
 
HTS03324 
 
2.27 ± 1.04 μM 
 
2.5 nM 
 
Stabilized* 
 
 
C16 
 
3.98 ± 3.88 µM 
 
2.5 – 25 µM 
 
Unchanged 
 
 
HTS13545 
 
4.11 ± 0.21 μM 
 
2.5 – 25 µM 
 
Stabilized* 
 
 
HTS10308 
 
5.24 ± 0.03 μM 
 
25 – 60 µM 
 
Unchanged 
 
 
DSHS00884 
 
~ 10 μM 
 
250 nM – 2.5 µM 
 
Stabilized 
 
 
CD11403 
 
10.9 ± 0.6 μM 
 
25 – 250 µM 
 
Unchanged 
 
 
Brazilin 
 
11.2 ± 4.2 µM 
 
25 – 250 nM 
 
Stabilized 
 
 
BTB 07267 
 
15.1 ± 1.8 μM 
 
250 nM – 2.5 µM 
 
Stabilized* 
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S05896 
 
15.7 ± 1.2 μM 
 
25 – 250 µM 
 
Unchanged 
 
 
HTS11967 
 
30.3 ± 10.9 μM 
 
250 nM – 2.5 µM 
 
Stabilized* 
 
 
D22 
 
36.9 ± 10.3 µM 
 
250 nM 
 
Unchanged 
 
 
Table 3.2: Secondary assay results summary for inhibitor compounds. The names, structures 
and secondary assay results for all thirty identified inhibitor compounds are listed in rank order 
of ELISA IC50 value.  ELISA IC50 values were determined by performing the assay in duplicate for 
each compound, normalization of data and subsequent data fitting in GraphPad with 
log(inhibitor) vs. response (variable slope) non-linear regression fit.  p53 degradation 
approximate IC50 is listed as a range.   The thermal stability result is as described in text.  
Asterisks denote compounds that showed E6 stability, but to a lesser degree. 
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3.3.3. Characterization of HPV-E6 Inhibitors in cells 
Through our high throughput screening assay and in vitro follow up assays, we identified 30 
compounds that inhibit E6-E6AP binding in an isolated system (ELISA) and a complex cell lysate 
(p53 degradation assay) so we next addressed whether these compounds could work in a 
cellular environment.  To do this, each compound was first tested in an MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay 
(Promega) to assess compound toxicity at a concentration range of 25 µM to 100 nM.  The 
control cell line used for this assay was C33A (ATCC), which is a tumor-derived, cervical cancer 
cell line that is not infected with HPV.   48 hours after the addition of compound, MTS assay 
reagent was added and the absorbance reading at 490 nm was directly related to the number of 
viable cells in the culture.  Some compounds were toxic in the 10 – 25 µM range, but none 
showed any sensitivity at concentrations below 10 µM (Figure 3.11, remaining data not shown). 
Each compound was then tested for its effectiveness at inhibiting p53 degradation in cells.  
Two different HPV-infected, tumor derived cell lines were used: SiHa (HPV16 integrated, ATCC) 
and HeLa (HPV18 integrated, ATCC).   48 hours after the addition of compound, cells were lysed 
and the level of p53 in each sample was assessed by Western blot using an anti-p53 antibody 
(Santa Cruz Biotechnologies).  4 compounds (DSHS 00884, RH02007, A22 and gossypetin) 
showed an increase in p53 levels in both cell lines over this concentration range while E17 and 
C22 protected against p53 degradation specifically in SiHa cells and C14 protected against p53 
degradation in HeLa cells (Figure 3.12, Figure 3.13). 
We were curious to determine if an increase in p53 levels could be correlated with 
apoptosis in the HPV-infected cells.  This question was approached with the APO-One assay 
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(Promega), which was carried out very similarly in HeLa cells to the MTS assay, except 48 hours 
after compound addition, a peptide bearing a rhodamine110 fluorescent tag was added to the 
wells.  The peptide is a substrate for caspases 3 and 7 and, upon cleavage, releases the 
rhodamine110 that when excited at 499 nm results in an increase in fluorescence at 521 nm.   
Based on this assays, two compounds showed an increase in apoptosis in both SiHa and 
HeLa cell lines while having minimal toxicity to C33A cells: DSHS 00884 and RH 02007 (Figure 
3.11, Figure 3.14, Appendix).  Both compounds fit the Lipinski guidelines for 
druglikeness(Lipinski et al, 1997).  According to the APO-One assay, caspase activity was 
increased nearly three-fold in cells treated with 10 µM or 250 nM DSHS 00884 over cells treated 
with DMSO alone (Figure 3.14). Similar to DSHS00884, the APO-one assay  result for RH 02007 
show that for cells treated with 10 µM RH 02007, a 2 fold increase in caspase 3 and 7 activities 
were seen (Figure 3.14).  In addition, cleaved Poly (ADP-ribose) polymerase (PARP), which is 
cleaved by caspase-3 during apoptosis, is also present in both cell lines treated with 10 µM 
RH02007(Ellis et al, 1991; Nicolettie & Stella, 2003; Trucco & al., 1998).  Given that the APO-one 
assay is very sensitive and PARP cleavage occurs late in the pathway, it is possible that the 
samples lacking cleaved PARP are either in the early stages of apoptosis or not enough cleaved 
PARP has accumulated that can be seen in a western blot.  Taken together, these data support 
that both of these compounds bring about an increase in p53 levels, which is correlated with an 
increase in apoptosis in HPV-positive cells. 
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Figure 3.11: Effect of E6 inhibitors on cell toxicity.  Normalized MTS assay data for C33A.  
Absorbance values were normalized against wells containing C33A + DMSO. 
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Figure 3.12: Effect of E6 inhibitors on p53 degradation in SiHa (HPV16) infected cells.  
Westerns of cell samples treated with increasing concentrations of compound. 
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Figure 3.13: Effect of E6 inhibitors on p53 degradation in HeLa (HPV18) infected cells.  
Westerns of cell samples treated with increasing concentrations of compound. 
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Figure 3.14: Effect of E6 inhibitors on apoptosis in HeLa (HPV18) infected cells.  Fluorescence 
data was normalized against HeLa cells treated with DMSO. 
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3.3.4. Discussion 
The purpose of this high throughput screen was to identify inhibitors of the E6-E6AP 
interaction with the downstream effect being protection against p53 degradation in HPV-
infected systems.  We identified 30 compounds that are able to block p53 degradation in a cell-
free system by a specific mechanism that does not involve E6 precipitation or degradation.  The 
extension of these compounds into HeLa and SiHa cells relies on the compound’s ability to get 
inside both cell types and to not be degraded over the time course of the experiment.   Four 
compounds were able to show protection against p53 degradation in both cell lines while three 
compounds were effective in one cell line and not the other.  It is conceivable that some of the 
remaining 23 compounds could be modified to more easily cross the cellular membrane and/or 
be made less resistant to degradation while still maintaining their E6/E6AP inhibitory properties. 
Of the compounds that were able to penetrate cells and mediate E6 inhibition, two induced 
apoptosis in the experimental 48 hour time period.  An increase in p53 levels can lead to any 
number of downstream effects so these compounds could be inducing cell cycle arrest or 
induction of DNA-damage repair genes instead.  A22, gossypetin, E17, C22 and C14, which all 
display inhibition of p53 degradation in both cell lines, shows no signs of apoptosis after 48 
hours.  Alternatively, these compounds may still be able to induce apoptosis, but not in the time 
frame of the experiment.  A recent study by DeFilipis et al looked at the HeLa cell response to 
the repression of the E6 gene(DeFilippis et al, 2003).  Apoptosis was not detected until six days 
post repression of the E6 gene.  It is conceivable that if these compounds were incubated to 
these time points, apoptosis would be detected.   
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The study reported here does provide some SAR information although it is quite limited at 
this point.  For example, gossypetin, brazilin and baicalein all fall within the same scaffold, 
particularly gossypetin and baicalein, which have similar results in all secondary assays.  Another 
related pair of compounds is HTS13545 and HTS10308, which differ only at one function group: 
HTS13545 bears a an amine group where HTS10308 has a double bonded oxygen.  Both have 
very similar IC50s, but HTS13545 stabilized E6M in the thermostability assay while HTS 10308 
does not.  Perhaps the amine group of HTS13545 donates two hydrogen bonds to its protein 
targeting leading to greater stabilization of the complex. 
While E6 binds p53, the other oncogenic protein E7 targets pRB to prematurely release E2F 
and bring about pRB degradation.  Both pathways are purposely inhibited so that viruses can be 
replicated.  Previous studies show that continual expression of these two genes is necessary to 
maintain malignancy while suppression of both genes results in cellular death(Alvarez-Salas & 
diPaolo, 2007).  While the studies reported here provide the first potent HPV-E6 inhibitors that 
might be further developed into therapeutic agents, other small molecules that can block pRB 
binding to E7 might take advantage of the synergistic effects of both compounds in a 
therapeutic setting to block HPV transforming effects and strongly bring about apoptosis in HPV-
infected cells. 
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3.4. Crystallization Results and Discussion 
 
3.4.1. E6M + MBP-E6AP 
As already discussed, a crystal structure of E6 has been long sought and fraught with 
problems.  Mainly, the protein has a strong propensity towards aggregation and precipitation.  
After several failed schemes, we were able to purify behaved E6M protein in large quantities but 
low concentrations after Ni-NTA purification.  However, this purified protein faced two 
problems: 1. when run over the superdex s200a column (GE Healthcare) for size-exclusion 
chromatography, > 90% of the protein bound the matrix and failed to elute, 2. the protein would 
not concentrate above 0.2 mg/mL.   
Luckily, the ~ 10% of protein that did elute from the gel filtration column was monomeric, 
which supports previous conclusions.  Also, purified E6M specifically pulled down the peptide of 
E6AP necessary and sufficient for binding (Figure 3.15).  Since E6M alone interacted with the gel 
filtration matrix and failed to concentrate, we considered the possibility that it may behave 
better when in the presence of a partner protein.  To this end, we purified E6M alone, mixed an 
equimolar amount of MBP-E6AP, concentrated the complex and performed size-exclusion 
chromatography.  One peak was seen on the gel filtration chromatogram at a size just larger 
than 44 kDa and an SDS-PAGE gel showed that both MBP-E6AP and E6M (complex 64.3 kDa) 
eluted together (Figure 3.16).  These fractions were then pooled, concentrated and used for 
crystallization trials.  One condition yielded crystals that were difficult to reproduce (Figure 
3.17). 
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Figure 3.15: Pulldown of E6AP by E6M.  Pulldowns were performed as described in the text.  
E6M specifically pulled down both MBP-E6AP (403 – 421, isoform II) and GST-E6AP (403 – 421, 
isoform II) but not MBP or GST alone. 
 
 
 
 
 
160 
 
 
Figure 3.16: Purification of E6M + MBP-E6AP6.  Representative superdex 200a gel filtration 
chromatogram for E6M + MBP-E6AP purification is shown.  The protein peaks just before the 44 
kDa standard, which fits for a complex of 64.3 kDa.  The 15% SDS-PAGE gel insert shows that the 
six fractions of the peak contain both proteins and that they elute together. 
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Figure 3.17: Crystals of the E6M + MBP-E6AP complex.  These crystals were obtained with 15 
mg/mL complex in 1.5 M NaCl and 10% v/v ethanol.  The tiny needles appeared after 
approximately one week. 
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3.4.2. E6M + DSHS 00884 
Encouraged by the success of binding E6 with MBP-E6AP for crystallization, we scoured the 
literature looking for other reported partner proteins.  Included in our studies were the CH3 and 
CH1 domains of p300, an E6 intrabody, and both N terminal and C terminal fusions of E6M with 
the E6AP peptide (known as N3 and C3).  We also tried three ternary complexes: E6M, MBP-
E6AP + p53DBD, N3 + p53DBD and C3 +p53DBD.  Unfortunately, none of these complexes 
resulted in crystals. 
The high throughput assay was designed to search for small molecules that disrupted the E6 
/ E6AP interaction with the hopes that several of these compounds would mediate their 
function by binding to E6.  Results of the thermostability assay show that some compounds are 
stabilizing E6 and are good choices for crystallization studies. 
One compound, DSHS00884, has currently been pursued (Figure 3.18).  Following 
purification of E6M, an equimolar amount of DSHS00884 was added and allowed to sit on ice for 
approximately one hour.  Figure 3.19 shows that E6M concentrated well in the presence of 
DSHS00884.  Crystallization trials were performed with complex at 1.8 mg/mL and several 
conditions yielded crystals (Figure 3.20), one of which had crystals that diffracted to 8 Å at the 
Advanced Photon Source (APS) microfocus beam.   
 Figure 3.21 shows the entire gel from the E6 + DSHS00884 preparation.  In addition to E6M, 
a lower band (SUMO tag) is seen as well as two much larger protein impurities.  It is unclear 
what protein actually crystallized.  The purification of E6M with DSHS 00884 was repeated and 
concentrated to 1.4 mg/mL, but yielded no crystals.  Because less impurities were present in the 
second preparation and the concentration was always determined by total protein amount, it’s 
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highly possible that E6M is a very different concentration in the second prep than the first.  It’s 
also a distinct possibility that we have crystallized an impurity, especially since the unit cell 
determined from the 8 Å data was very large. 
Due to these problems, the procedure for purifying E6M would benefit from some 
improvements.  Primarily, a way to remove impurities is necessary, especially since the 
impurities are not a big problem initially, but become so during concentration since E6M 
concentrates slower than the contaminants.  Several possibilities have been attempted, but 
none to any great success because of the need for high salt concentrations and tendency of the 
protein to interact nonspecifically with resins.   The best possibility may be to covalently link one 
of the indentified compounds to resin and pass the impure E6M over it, then elute the protein 
with either excess of the same compound or another compound that can compete with the 
resin. 
Regardless, 18 compounds have been identified from high throughput screening that have 
the potential to stabilize E6 for crystallization studies and need to be pursued as such.  Perhaps 
a crystal structure of E6 is on the horizon. 
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Figure 3.18: Thermostability assay curves for E6M + DMSO, DSHS00884.  Replicate data (blue 
and red) for fluorescence at 580 nm vs temperature for DMSO (top) and DSHS 00884 (below) is 
shown.  Inherent protein instability is seen in the region of 20°C and 37°C for E6M + DMSO.  This 
region of instability is significantly flatter in E6M + DSHS 00884. 
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Figure 3.19: Concentration of the E6M + DSHS00884 complex.  The first lane shows E6M after 
purification from the Ni-NTA resin.  The next three samples were taken during various stages of 
concentration.  The final lane is E6M + DSHS 00884 at a concenetration of 1.8 mg/mL. 
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Figure 3.20: Crystals of the E6M + DSHS00884.  These crystals were obtained with E6M + DSHS 
00884 concentrated to 1.8 mg/mL in 200 mM ammonium citrate tribasic, pH 7.0 and 20% PEG 
3350.  They appeared after ~ 3 days. 
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Figure 3.21: Full gel of E6M + DSHS00884 concentration.  This is a larger view of the gel from 
Figure 3.19.  A lower contaminating band, which is the SUMO tag, is seen as well as two much 
larger contaminating bands, whose identity is unknown. 
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3.5. Future Work 
Aside from the crystallization studies that need to be pursued, follow up work on the 
compounds still needs to be completed.  Several compounds inhibit p53 degradation in cells but 
do not appear to induce apoptosis.  Since p53 function includes cell cycle arrest and induction of 
DNA-damage repair genes, it is possible that these compounds are mediating their function 
towards these ends.  It would also be interesting to determine if some of the 23 compounds that 
did not work in cells could be modified to improve their behavior without loss of function.  
Finally, definitively showing the ability of these compounds to directly bind E6 would allow for 
structure-activity relationship (SAR) studies to find more compounds that can inhibit E6 function 
at greater potencies and lower toxicity. 
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APPENDIX  
Liquid Chromatography - Mass Spectrometry Results for RH 02007 and DSHS 00884 
 
 
 
Figure A.1: LC-MS results for RH 02007.  Predicted molecular weight for the compound is 312.32 
g/mol.  The data supports a molecule of 310.3 Da, which is a discrepancy of 2 Da (top panel).  
The middle panel shows the predicted break down of peaks around 312 Da for the compound 
based on its chemical structure and the bottom panel shows the actual break down of peaks.   
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Figure A.2: LC-MS results for DSHS 00884.  Predicted molecular weight for compound is 308.39 
g/mol, which is confirmed by the data (top panel).  The middle panel shows the predicted break 
down of peaks around 308 Da for the compound based on its chemical structure and the bottom 
panel shows the actual break down of peaks.  Both panels are the same. 
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